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Myosin XVI is a neuronally expressed member of the myosin superfamily. Many aspects 
of this myosin remain mysterious, but its ability to regulate actin branching and 
indications of its enhanced expression in early development indicate a role in brain 
development. Intriguingly, the gene encoding myosin XVI has been linked to autism 
spectrum disorder and schizophrenia which both display disrupted neurodevelopment. 
Both are complex, debilitating and currently incurable conditions that have partly 
overlapping symptoms, including olfactory abnormalities that have recently attracted 
more interest.  
 
This Master’s Thesis investigated the subcellular localization and developmental 
expression of myosin XVI to enlighten its role in the brain. Localization pattern and 
interaction with filamentous actin were studied in human osteosarcoma cells by staining. 
The expression pattern was examined in the postnatal mouse olfactory bulb, 
hippocampus, cerebellum, and cortex by western blotting. The results suggest a principal 
localization to the perinuclear region where myosin XVI may regulate vesicle traffic. 
Myosin XVI was also observed to co-localize with actin on the cell membrane where it 
may regulate membrane protrusion. Additionally, findings indicate a role in cell division. 
Western blotting revealed a higher expression in early postnatal development compared 
to later stages, apart from the olfactory bulb where the expression remained more stable. 
 
These observations support the hypothesis that myosin XVI can regulate 
neurodevelopment. Future research will need to clarify the molecular mechanisms and 
cellular distribution of myosin XVI in the brain, especially in the olfactory bulb. This can 
add to understanding of autism spectrum disorder and schizophrenia and, ultimately, 
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1.1 Myosins and actin 
Myosins are eukaryotic proteins that constitute a large and versatile superfamily of at least around 20 
distinct myosin classes, likely many more (Foth et al., 2006; Sebé-Pedrós et al., 2014). These classes 
can further be divided into different subclasses (Sebé-Pedrós et al., 2014). Myosin classes are 
typically denoted by Roman numerals. Myosin class II was discovered first and myosins from this 
family thus referred to as conventional, whereas members of the other classes are designated as 
unconventional (Sellers, 2000).  
Myosins come in many different forms, but they all share a motor, also known as head, domain at the 
N-terminus, a neck domain in the middle, and a tail domain at the C-terminus of their heavy chains 
(Foth et al., 2006; Hartman and Spudich, 2012). The head domain is highly conserved across different 
myosins and is the domain responsible for the famous motor function of myosins; it contains binding 
sites for adenosine triphosphate (ATP) and actin, and functions as a mechanoenzyme, or ATPase, that 
converts the chemical energy of ATP into mechanical force by hydrolysis (Hartman and Spudich, 
2012; Sellers, 2000). The conformational changes in the ATP-binding site enable cyclic interactions 
between the myosin and actin (Hartman and Spudich, 2012). The neck domain can interact with 
myosin light chains and likely serves as a regulatory region (Foth et al., 2006). The tail domain, in 
turn, varies greatly between different myosin classes and is thought to be the major domain 
responsible for the diverse functions myosins play in cells (Foth et al., 2006; Hartman and Spudich, 
2012). The tail domain may contain different functional motifs and typically binds adaptor proteins 
and other cellular binding partners that myosins interact with (Hartman and Spudich, 2012; Sellers, 
2000).  
As a consequence of their ability to interact with actin and to bind various other cellular molecules, 
myosins are known to be important for a wide repertoire of cellular processes (Hartman and Spudich, 
2012; Krendel and Mooseker, 2005). Actin is a protein that is arranged into filaments that constitute 
the actin cytoskeleton of the cell (Carlsson, 2010). The actin cytoskeleton is a dynamic structure that 
undergoes continuous cycles of nucleation of new actin filaments from actin monomers, elongation 
of actin filaments by polymerization to produce filamentous actin (F-actin), and filament severing 
and depolymerization (Carlsson, 2010). F-actin is found principally in the cytoplasm, where it is 
organized into different linear and cross-linked meshworks (Svitkina, 2018). The dynamic 
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reorganization allows the actin cytoskeleton to provide support to the cell and act as an intracellular 
transportation network (Carlsson, 2010). Myosins are known to regulate many actin-related activities 
in the cell, including cell migration, cell adhesion, cytokinesis, intracellular transport, organelle 
anchoring, and membrane trafficking (de Lanerolle, 2012; Hartman and Spudich, 2012; Krendel and 
Mooseker, 2005).  
1.2 Myosin XVI 
1.2.1 Structure 
The unconventional myosin class XVI (MYO16, also known as KIAA0865 and NYAP3) is a 
relatively recently found member of the myosin superfamily. It was initially screened from human 
by Nagase and colleagues in 1998, but the first systematic characterization of this myosin class was 
conducted by Patel and colleagues in 2001 (Nagase et al., 1998; Patel et al., 2001). Myosin XVI is 
only found in vertebrates and is likely specific to mammalian species, including human, which 
indicates that it developed rather late in the course of myosin evolution (Krendel and Mooseker, 2005; 
Thompson and Langford, 2002).  
Patel et al. (2001) identified two myosin XVI subclasses, or isoforms, in rat (Figure 1). One isoform 
comprised a heavy chain of 1912 amino acids and the other a heavy chain of 1322 amino acids. These 
two isoforms appeared to display unique structural features in both the N-terminal and C-terminal 
domains. First, they have an extension at the N-terminus prior to the motor domain. This pre-motor 
domain contains a conserved myosin phosphatase N-terminal element, a protein phosphatase type 1 
catalytic subunit-binding motif, and several ankyrin repeats (Patel et al., 2001; Telek et al., 2020). In 
addition, the pre-motor domain possesses a nuclear export signal (NES) sequence (Cameron et al., 
2007). The pre-motor domain is followed by a motor domain that is highly similar to motor domains 
of other myosins, containing ATP- and actin-binding motifs (Patel et al., 2001). Next comes a short 
neck domain that contains one calmodulin-binding motif (Patel et al., 2001; Telek et al., 2020). After 
that begins the C-terminal tail domain, which also distinguishes the two isoforms as it is truncated in 
the shorter one (Patel et al., 2001). In the longer isoform, the tail domain includes a Wiskott–Aldrich 
syndrome protein/verprolin homologue 1 (WAVE1)-interacting region, and a neuronal tyrosine-
phosphorylated adaptor for phosphoinositide 3-kinase (NYAP) homology motif (NHM) containing a 
nuclear localization signal (NLS) sequence and tyrosine residues, as well as a proline-rich region 
(Cameron et al., 2007; Patel et al., 2001; Telek et al., 2020). 
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The precise tertiary as well as potential quaternary structure of myosin XVI remains ambiguous as 
X-ray crystallography has not been performed. It is however likely that the two myosins of class XVI 
exist as monomers, because they appear to be most closely related to monomeric myosin class III 
members and because the tail domain does not contain motifs typically required for protein 
dimerization (Cameron et al., 2007; Patel et al., 2001).  
 
Figure 1. A schematic representation of the structure of myosin XVI isoforms A and B (adapted from Bugyi and Kengyel, 
2020, and Telek et al., 2020). The amino acids are numbered and correspond to the rat isoforms. MyPhoNE, myosin 
phosphatase N-terminal element. KVxF, protein phosphatase type 1 catalytic subunit-binding motif. NES, nuclear export 
signal. IQ, calmodulin-binding motif. WIR, WAVE1-interacting region. NLS, nuclear localization signal. NHM, NYAP 
homology motif. PRR, proline-rich region. 
 
The UniProtKB/Swiss-Prot database proposes four myosin XVI splice variants in human (NCBI 
RefSeq: NP_055826.1). The longest one, encoding for a heavy chain of 1858 amino acids, likely 
corresponds to the rat 1912 amino acid isoform with longer tail domain, based on sequence analyses 
(Patel et a., 2001; UniProtKB/Swiss-Prot). As for mouse, the UniProtKB/Swiss-Prot database 
describes three potential myosin XVI splice variants (NCBI RefSeq: NP_001306080.1), and the two 
longest ones, constituting 1919 amino acids, also likely correspond to the rat 1912 amino acid 
isoform. The deducted molecular masses for the long-tail myosin XVI isoforms in human, rat, and 




From now on, myosin XVI is used as a principal term when describing the protein in general. MYO16 
(gene name MYO16) is used when discussing specifically the human form, whereas Myo16 (gene 
name Myo16) is used when discussing specifically the mouse or rat form. Likewise, the short-tail 
isoform myosin is designated as XVIA, MYO16A, or Myo16a, and the long-tail isoform as myosin 
XVIB, MYO16B, or Myo16b.  
1.2.2 Cellular and subcellular distribution 
Myosin XVI is expressed in many tissues, but its expression is enhanced in the central nervous system 
(Patel et al, 2001; The Human Protein Atlas). In rat, Myo16b is the principal isoform both in the brain 
and in the periphery, and Myo16a is expressed in considerably smaller quantities (Patel et al., 2001). 
Myosin XVI does not display prominent regional differences in the brain, but the expression level 
may be related to the developmental stage (Patel et al., 2001; The Human Protein Atlas). The 
expression of myosin XVI has mostly been studied in the rodent brain, especially in the cerebral 
cortex and cerebellum, but expression has also been detected widely in the human brain where 
MYO16 is found in the cerebral cortex, cerebellum, the limbic system including structures such as 
the hippocampus, olfactory region, and amygdala, and in many other regions (Patel et a., 2001; 
Roesler et al., 2019; The Human Protein Atlas; Yokoyama et a., 2011).  
Myosin XVI is an intracellular protein. In primary rat astrocytes, cerebellar granule neurons, and 
hippocampal neurons, it localizes throughout the cytoplasm in a punctate manner, and occasionally 
to the intracellular surface of plasma membrane and around the nucleus (Patel et al., 2001). In mouse 
cerebellar Purkinje cells, Myo16 localizes to dendritic spines (Roesler et al., 2019). In the human 
fibroblast-like COS-7 cell line, MYO16 shows variable locations, including the cytoplasm and the 
nucleus (Cameron et al., 2007). Inside the nucleus, it appears to localize diffusely in the nucleoplasm, 
excluding the nucleoli (Cameron et al., 2007; Cameron et al., 2013). MYO16 has also been described 
in vesicles in the neuronal SH-SY5Y cell line (The Human Protein Atlas). Previous results indicate 
that the myosin XVIA isoform is cytoplasmic but the B isoform is both cytoplasmic and nuclear 
(Bugyi and Kengyel, 2020; Cameron et al., 2013). The localization might be dependent on the phase 
of the cell cycle, which would explain the variable locations (Cameron et al., 2013). 
1.2.3 Molecular interactions and proposed biological functions 
The KVxF motif in the pre-motor domain of myosin XVI corresponds to the consensus protein 
phosphatase type 1 catalytic subunit (PP1c) sequence identified in many PP1c-binding proteins (Patel 
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et al., 2001). Myosin XVI is therefore assumed to interact with PP1c and control dephosphorylation 
of intracellular proteins (Kengyel et al., 2015; Patel et al., 2001). Considering the ability of PP1c to 
regulate a broad range of cellular functions, it is likely that the pre-motor domain of myosin XVI has 
important roles in contributing to its functions (Cohen, 2002; Kengyel et al., 2015). However, the 
specific outcomes of the interaction with PP1c are not yet known. Ankyrin repeats are commonly 
known to mediate protein–protein interactions, which indicates that the pre-motor domain of myosin 
XVI may contribute to the function through various other intermolecular interactions as well (Mosavi 
et al., 2004). In addition, the pre-motor domain may also modulate intramolecular interactions, such 
as the ATPase activity of the motor domain (Kengyel et al., 2015).  
The motor domain of myosin XVI co-sediments with F-actin in an ATP-sensitive manner and is 
therefore assumed to function as an ATPase as most other myosins (Patel et al., 2001). This function 
has not been established, however, and more recent sequence analyses propose that myosin XVI may 
have a reduced ATPase activity (Cameron et al., 2007). 
The long tail domain of myosin XVIB has attracted special interest as it is considered to mediate the 
major cellular function of the protein. The NHM motif in the tail domain contains tyrosine residues 
that can be phosphorylated by a protein-tyrosine kinase FYN, induced by Contactin (Yokoyama et 
al., 2011) (Figure 2). Presumably mediated by this phosphorylation, myosin XVIB can interact with 
the p85 subunit of phosphoinositide 3-kinase (PI3K) (Yokoyama et al., 2011). This leads to activation 
of the downstream effector proteins of the PI3K pathway, such as RAC1, which in turn triggers the 
activation of the WAVE1 subunit of the WAVE regulatory complex (WRC) (Yokoyama et al., 2011). 
Myosin XVIB can also directly interact with components of the WRC, through the region located 
prior to the NHM motif in the protein sequence (Yokoyama et al., 2011). The activated WRC further 
stimulates the actin-related protein 2/3 (Arp2/3) complex that is responsible for nucleation of 
branched actin filaments (Goley and Welch, 2006; Takenawa and Suetsugu, 2007). Hence, myosin 
XVIB isoform likely regulates reorganization of the actin cytoskeleton by activating the PI3K–WRC–
Arp2/3 pathway and by recruiting the WRC near to PI3K to facilitate the conversion of signals into 
action. Additionally, the proline-rich region in the tail domain of myosin XVIB possibly comprises 
binding sites for profilin and ENA/VASP homology proteins, suggesting that it also interacts with 
these regulators of actin polymerization (Patel et al., 2001; Prehoda et al., 1999). For instance, 
ENA/VASP proteins are associated with actin-dependent cell motility are required for targeting the 
actin polymerization machinery to sites of cytoskeletal remodeling where they affect the function of 




Figure 2. A simplified illustration of the proposed intracellular signaling pathway of myosin XVIB in the regulation of 
the branched actin formation (adapted from Telek et al., 2020). Tyrosine residues (P) in the tail domain of myosin XVIB 
are phosphorylated by FYN, which triggers activation of phosphoinositide 3-kinase (PI3K). PI3K converts 
phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3) on the plasma 
membrane. PIP3 in turn activates downstream signaling molecules, such as RAC1 that further activates the WAVE 
regulatory complex. The WAVE regulatory complex stimulates Arp2/3 complex that is responsible for nucleation of 
branched actin filaments. Myosin XVIB may also have direct interactions with the WAVE regulatory complex through 
the WAVE1-interacting region of the tail domain. 
 
 
Arp2/3 complex activity and branched actin formation are important for many cellular events. These 
include 1) organization of lamellipodial protrusions at the leading edge of the cell during migration, 
2) organization of adhesion sites, 3) intracellular vesicle transport, and 4) endocytosis and exocytosis, 
for example (Goley and Welch, 2006) (Figure 3).  
 
 
Figure 3. An illustration of some locations of the Arp2/3 complex and branched actin filaments (red) in the cell (adapted 
from Goley and Welch, 2006). Branched actin is found in lamellipodia which are located linearly to the leading edge of 
the cell. Branched actin is also found at focal contact sites. In addition, branched actin formation is required for 





















Since myosin XVI is highly expressed in the brain, earlier studies have aimed to elucidate its role 
there. Previous studies suggest that myosin XVI expression depends on the developmental stage, 
being highest shortly after birth, and also that myosin XVI is most active during the period of pre- 
and neonatal brain development (Patel et al., 2001; Yokoyama et al., 2011). More specifically, myosin 
XVI may regulate neurite outgrowth and regulation of dendritic spines and synapses in the developing 
brain. These are discussed next. 
Neurite outgrowth refers to the growth of dendrites and axons from the neuronal cell body (Sainath 
and Gallo, 2015). Myosin XVI is supposed to regulate neurite elongation and also neuronal 
morphogenesis through its actions on PI3K signaling, triggering not only the PI3K–WRC–Arp2/3 
pathway but possibly other parallel pathways as well (Yokoyama et al., 2011). Two types of actin-
rich projections are found at the leading edge of the elongating neurites; filopodia and lamellipodia 
(Sainath and Gallo, 2015). Arp2/3 complex activity and actin branching is frequently ongoing in 
lamellipodia (Goley and Welch, 2006). Therefore, it is possible that myosin XVI operates there. 
Synaptic function largely depends on the structure and disposition of dendritic spines (Hotulainen 
and Hoogenraad, 2010). Dendritic spines are small protrusions that bulge from the main shaft of 
dendrites and are found postsynaptically at most excitatory synapses (Bourne and Harris, 2008; 
Hering and Sheng, 2001; Hotulainen and Hoogenraad, 2010). Dendritic spines are enriched with 
branched actin (Hotulainen and Hoogenraad, 2010). They are typically found in both excitatory and 
inhibitory neurons, however several classes of neurons also lack dendritic spines, such as many 
inhibitory interneurons (Hering and Sheng, 2001; Scheuss and Bonhoeffer, 2014). Changes in the 
size, shape, and distribution of dendritic spines are thought to serve as the molecular basis for synaptic 
plasticity, and the spines are considered as the major sites for information processing and storing in 
the brain (Hering and Sheng, 2001; Hotulainen and Hoogenraad, 2010). For example, alterations in 
the structure and function of the spines in hippocampal neurons are among the key determinants of 
neural processes underlying learning and memory (Bourne and Harris, 2008).  
Logically, then, disturbances in the PI3K–WRC–Arp2/3 pathway can jeopardize the function of 
dendritic spines and thereby neuronal plasticity. For example, hippocampal neurons from Wave1 
knockout mice have abnormal neuronal morphology, growth cone dynamics, and dendritic 
development, density, and receptor composition (Soderling et al., 2007). Similarly, hippocampal 
neurons from Arp2/3 subunit knockout mice show functionally immature synapses and structurally 
deficient dendritic spines (Hotulainen et al., 2009; Spence et al., 2016). Myosin XVI, a regulator of 
both WRC and Arp2/3 as discussed above, has also been found in dendritic spines in cerebellar 
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Purkinje cells in mice (Roesler et al., 2019). In Myo16 knockout mice, actin turnover is accelerated 
in the dendritic spines of Purkinje cells, indicating that depletion of myosin XVI may result in a faster 
actin turnover rate (Roesler et al., 2019). However, the density of dendritic spines remains unaltered 
in Purkinje cells lacking myosin XVI as compared to cells where the protein is normally expressed 
(Roesler et al., 2019). In addition to its proposed postsynaptic functions, myosin XVI also appears to 
be important for presynaptic structure as well as for the number of synaptic vesicles (Roesler et al., 
2019). Myosin XVI may also participate in cell adhesion at synapses. Some findings indicate that it 
interacts with neurexin 1- (NRXN1), a pre-synaptic membrane cell adhesion molecule, and with 
Kin of IRRE-like protein 3 (KIRREL3), another synaptic protein that participates in cell adhesion 
(Liu et al., 2015; Nakayama et al., 2002).  
Two more identified binding partners of myosin XVI are GTPase Regulator Associated with Focal 
Adhesion Kinase-1 (GRAF1) and Acyl-CoA thioesterase 9 (ACOT9) (Yokoyama et al., 2011). 
Interaction with GRAF1 suggests that myosin XVI may play a part in endocytic events, as GRAF1 
regulates the clathrin-independent endocytic pathway (Lundmark et al., 2008). Interaction with ACOT9 
suggests a role in intracellular fatty acid metabolism, since ACOT9 hydrolyzes Coenzyme A esters 
(Tillander et al., 2014). 
Finally, myosin XVI may also participate in regulation of the cell cycle (Cameron et al., 2007; 
Cameron et al., 2013). The PI3K pathway is essential not only for Arp2/3-dependent formation of 
branched actin but also for various other cellular events, including neuronal survival and 
differentiation, supporting this hypothesis (Laurino et al., 2005; Rodgers and Theibert, 2002). 
Cameron et al. (2007, 2013) have found that the subcellular localization and expression level of 
myosin XVI may vary depending on the phase of the cell cycle. Expression of myosin XVI mRNA 
is highest during the interphase when the subcellular localization of the protein is restricted to the 
nucleus and is reduced during mitosis when the protein is dispersed outside the nucleus (Cameron et 
al., 2007; Cameron et al., 2013). Myosin XVI may regulate progression of the cell cycle, so that loss 
of myosin XVI can even lead to apoptosis (Cameron et al., 2013). The function in cell cycle regulation 
is supported by the NLS and NES sequences found in myosin XVI. The presence of these sequences 
implicates that myosin XVI may shuttle between the nucleus and cytoplasm; NLS tags a protein to 




1.3 Myosin XVI and mental disorders 
1.3.1 Autism spectrum disorder 
Autism spectrum disorder (ASD) comprises a group of conditions that are manifested by a lack of 
social and emotional interaction and communication, stereotypic behaviors (e.g., repetitive 
movements), restricted interests, problems with speech and language, and often also cognitive, 
sensory, and motor abnormalities (Abrahams and Geschwind, 2008; Hodges et al., 2020; Vijayajumar 
and Judy, 2015). As the word ‘spectrum’ indicates, ASD is an umbrella term under which there are 
variable conditions ranging from mild to severe (Vijayajumar and Judy, 2015). Although each 
individual affected by ASD has a unique combination of symptoms, ASD is typically classified into 
four main categories, namely Asperger’s syndrome, classical autistic disorder, childhood 
disintegrative disorder, and pervasive developmental disorder not otherwise specified (Vijayajumar 
and Judy, 2015). First symptoms of ASD typically emerge early in development, before the age of 
three years (Hodges et al., 2020). The prevalence of ASD is estimated to be around 1% globally, and 
it appears to be higher in males and in Caucasian populations (Hodges et al., 2020).  
Sensory symptoms are a newer category included in the diagnostic criteria of ASD, as they have been 
increasingly recognized as one of the central symptoms (Hodges et al., 2020). It has been proposed 
that the sensory symptoms are not just secondary symptoms but instead directly grounded in the 
pathophysiological mechanisms of ASD, and even that the sensory abnormalities may lead to other 
behavioral impairments (Hazen et al., 2014). Sensory symptoms include sensory hyperreactivity, 
sensory hyporeactivity, and sensory-seeking behavior which refers to showing special interest in 
sensory information of the environment (Hazen et al., 2014; Hodges et al., 2020). Sensory stimuli 
can encompass any of the five senses, but abnormalities in smell, taste, and touch have been reported 
to be most common (Hazen et al., 2014). In terms of the sense of smell, several studies have found 
that detection and identification of olfactory stimuli is significantly worsened in autistic individuals 
compared to non-affected individuals (Bennetto et al., 2007; Sweigert et al., 2020). Sensory 
symptoms appear to be highly prevalent, as studies suggest that 55–70% of autistic people have these 
(Hazen et al., 2014).  
Despite extensive research, the etiology of ASD remains elusive (Chen et al., 2015). High heritability, 
confirmed by twin and family studies, however points to strong contribution of genetic factors (Bailey 
et al., 1995; Folstein and Piven, 1991; Messinger et al., 2013). In addition to inherited mutations or 
variations, non-heritable de novo variants are also common (Chen et al., 2015). A large number of 
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genes contributing to ASD have been identified in many different studies, yet much of the genetic 
variation in ASD remains inexplicable (Manolio et al., 2009; Roberts et al., 2014; Wang et al., 2009). 
Although the genetic basis of ASD is now undisputed, environmental factors also play a part and are 
likely entangled with the genetic mechanisms (Vijayajumar and Judy, 2015). The current view on 
genetics is that in most cases ASD is caused by a combination of multiple genetic risk variants that 
each have only a small effect on the pathogenesis, rather than by a single gene (Cook and Scherer, 
2008). This has complicated the elucidation of the etiology as ASD is a very heterogenous condition 
(Chen et al., 2015). It is likely that ASD comprises several different subphenotypes (Hu and 
Steinberg, 2009). 
The well-established view is that ASD is a neurodevelopmental condition (Chen et al., 2015). But 
how exactly it affects the nervous system is not clear. An increased overall brain size during the early 
childhood is a typical finding in ASD, as well as abnormalities in the cytoarchitecture of the cerebral 
cortex, cerebellum, and parts of the limbic system such as the hippocampus and amygdala (Chen et 
al., 2105). Current models of ASD pathophysiology propose dysconnectivity of brain networks, 
neuroinflammation, growth dysregulation, abnormal synaptogenesis and synaptic dysfunction, 
altered serotonin activity, and altered signaling between neurons and glial cells, among other 
hypotheses (Chen et al., 2015; Kennedy and Adolphs, 2012; Samsam et al., 2014). Synaptic 
dysfunction is supported by mutations in synaptic proteins and findings of dendritic spine 
abnormalities, imbalances in excitatory/inhibitory neurotransmission, and a decreased number of 
inhibitory interneurons (Chen et al., 2015; Penzes et al., 2011; Zoghbi and Bear, 2012). 
1.3.2 Schizophrenia 
Schizophrenia is a neuropsychiatric disorder characterized by positive, negative, and cognitive 
symptoms (Millan et al., 2016). Positive symptoms – referring to experiences that are present when 
they should be absent – include psychotic behaviors, such as delusions and hallucinations (Millan et 
al., 2016). Negative symptoms – referring to experiences that are absent when they should be present 
– include flattened emotional expression and feelings, lack of pleasure and motivation, and decreased 
speech, for example (Millan et al., 2016). Cognitive symptoms include disorganized thinking and 
speech, and deficits in executive function (Millan et al., 2016). In addition, individuals with 
schizophrenia often exhibit impairments in motor and social function, such as social withdrawal, and 
sensory abnormalities (Millan et al., 2016). The typical onset of schizophrenia is during late 
adolescence or early adulthood (Forrest et al., 2018). 
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Sensory symptoms are common in schizophrenia, and they appear to extend beyond the visual and 
auditory hallucinations traditionally associated with it (Javitt, 2009). For example, olfaction is one of 
the sensory systems often affected (Javitt, 2009; Moberg et al., 2014). Schizophrenic individuals 
frequently exhibit substantial impairments in their ability to sense, identify, and discriminate odors 
(Moberg et al., 2014). An impaired sense of smell may even predict the development of psychosis 
(Moberg et al., 2014). 
Like ASD, schizophrenia is an etiologically and symptomatically complex and chronic disorder that 
affects about 1% of the population worldwide (Millan et al., 2016). Many genetic, epigenetic, and 
environmental risk factors have been identified, but a comprehensive understanding of the 
pathogenesis remains unattained (Millan et al., 2016; Patel et al., 2014). Schizophrenia is also 
considered to be a result of disrupted neurodevelopment (Millan et al., 2016). Brain imaging findings 
point to structural and functional abnormalities in the cerebral cortex, hippocampal region, thalamus, 
and cerebellum, as well as in white matter tracts and ventricles (Andreasen and Pierson, 2008; 
Harrison, 1999; Millan et al., 2016; Van den Heuvel and Fornito, 2014). Plausible pathophysiological 
mechanisms include unbalanced glutamate and dopamine neurotransmission, aberrant neuronal 
connectivity, altered synaptic development and dendritic spines, and interneuron dysfunction (Marin, 
2012; Moghaddam et al., 2012; Patel et al., 2014; Penzes et al., 2011; Pettersson-Yeo et al., 2011; 
Rapoport et al., 2012). 
1.3.3 Links between MYO16, ASD, and schizophrenia 
Genetic studies have found that MYO16 is one of the genes linked to ASD. This is evident in genetic 
databases collecting results from many different ASD patient cohorts (DECIPHER, SFARI). One 
method to study the genetic risk factors is the genome-wide association studies that usually aim to 
identify single nucleotide polymorphisms (SNPs) in case–control cohorts (Connolly et al., 2013). 
Another common method, chromosomal microarray analysis, can detect copy number variants such 
as deletions and duplications (Roberts et al., 2014). A meta-analysis combining analyses from two 
large ASD cohort studies revealed eight SNPs, at the chromosomal locus 13q33.3 near the MYO16 
gene, that may be associated with ASD (Wang et al., 2009). Another study identified five SNPs with 
suggestive association to ASD in the intergenic region between MYO16 and IRS2 genes in males, but 
not in females, affected by ASD (Chang et al., 2013). This intergenic region is not presumed to 
contain any protein-coding genes, suggesting that although the MYO16 gene itself may remain 
unaffected, the regulatory elements controlling its transcription can mediate harmful effects (Chang 
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et al., 2013). Three more studies found that some patients with ASD have deletions in MYO16 
(Friedman et al., 2009; Liu et al., 2015; Tucker et al., 2011).  
Nevertheless, myosin XVI may affect the pathogenesis of ASD also indirectly. Many of the risk genes 
that predispose to ASD encode proteins that participate in regulation of neurite outgrowth, cell 
adhesion, synapse formation and maintenance, indicating that they act on common pathways in the 
cell (Joensuu et al., 2018; Liu et al., 2016). Assuming that myosin XVI is a crucial player in actin 
cytoskeleton remodeling and synapse regulation, disruptions in the function of other proteins working 
together with myosin XVI in these roles may result in altered function of myosin XVI as well. 
Suggestive to this possibility are the findings that myosin XVI may interact with some synaptic 
proteins, such as KIRREL3 and NRXN1, whose mutations have been linked to ASD (Gauthier et al., 
2011; Liu et al., 2015; Nakayama et al., 2002) 
MYO16 has also been linked to schizophrenia (Rodriguez-Murillo et al., 2014; SZDB). According to 
SZDB gene database, alterations in MYO16 are usually intronic SNPs. One study employing exome 
sequencing of schizophrenic patients found that SNP in MYO16 results in a loss-of-function mutation 
(Kenny et al., 2014). 
1.3.4 Shared features of ASD and schizophrenia 
ASD and schizophrenia may seem unrelated at first glance, but they share several features. First, both 
are intricate and heterogenous conditions with unclear root causes. A strong genetic basis and an 
interplay between genetic and environmental factors is evident in both. A large pool of genes that 
may contribute to the pathogeneses have been identified in both ASD and schizophrenia, and common 
genes and genetic loci have also been found (Kenny et al., 2014; Millan et al., 2016). One of the genes 
reported to be affected in both disorders is MYO16. 
Second, both ASD and schizophrenia display aberrant neurodevelopment. The time of onset of the 
symptoms in these disorders, the early childhood in ASD and late adolescence or early adulthood in 
schizophrenia, also coincides with the period of vigorous brain development and maturation 
(Andersen, 2003). Key processes in brain development include cell differentiation, migration, neurite 
outgrowth, formation and pruning of synapses, and establishment of synaptic connections and 
neuronal networks (Andersen, 2003). In human, early childhood in particular is characterized by rapid 
neurite outgrowth, generation of glial cells, and establishment of synaptic connections, but 
remarkable structural and molecular reorganization of cells and synapses continues at least until 
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adolescence (Zhao and Bhattacharyya, 2018). ASD and schizophrenia may affect similar biological 
processes, including the regulation of synaptic function, neuronal connectivity, and interneurons. 
Abnormal dendritic spines are found in both disorders, and it has been hypothesized that the number 
of dendritic spines is higher than normal in autistic individuals and lower than normal in 
schizophrenic individuals (Penzes et al., 2011). On the other hand, some studies have indicated that 
the expression of MYO16 is lower than normal in the autistic brain and higher than normal in the 
schizophrenic brain (Liu et al., 2015; Rodriguez-Murillo et al., 2014). Aberrant regulation of dendritic 
spines could affect synapse formation, elimination, and maintenance, and further compromise the 
normal neurodevelopment (Penzes et al., 2011). In addition to these mechanisms, ASD and 
schizophrenia likely affect the same brain structures, such as the cerebral cortex, the limbic system, 
and the cerebellum.  
Third, autistic and schizophrenic individuals display partly similar symptoms. These include social 
deficits, cognitive problems, and sensory abnormalities, which may be rooted in the disrupted 
development of the cerebral cortex, cerebellum, and the limbic system. Interestingly, abnormalities 
in olfaction have been reported in both ASD and schizophrenia, most often impairments in 
identification and discrimination of olfactory stimuli. Olfactory bulb is part of the limbic system and 
the first site of odor processing in the mammalian brain (Su et al., 2009). It relays olfactory 
information to other brain areas but also itself participates in odor recognition, discrimination, and 
odor-induced behavior (Su et al., 2009).  
Finally, one more uniting feature of ASD and schizophrenia is the lack of effective treatments. At 
present, pharmacological interventions are inexistent in ASD and only partially effective in 
schizophrenia (Patel et al., 2014). For schizophrenia, a combination of psychotherapy and 
pharmacological therapy is often most effective (Patel et al., 2014). Pharmacological treatment is 
usually essential for the everyday functioning (Patel et al., 2014). Pharmacological options include 
several traditional and second-generation antipsychotics, however many patients suffering from 
schizophrenia do not respond to them (Patel et al., 2014). Clozapine is the most effective drug, but 
its significant disadvantage is the risk of developing agranulocytosis as well as electrolyte imbalances, 
both very dangerous side effects (Patel et al., 2014). In addition, there are unfortunately many patients 
who do not benefit from any medication (Patel et al., 2014). As for ASD, treatment is mainly limited 
to psychotherapy, although different medications have been tested and are used to alleviate specific 
symptoms and comorbidities accompanying the condition (DeFilippis and Wagner, 2016). 
Treatments of schizophrenia and especially those of ASD are currently only symptomatic, and 
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therapies that could cure these disorders do not exist. In the past decades, drug development in the 
field of mental disorder has generally appeared to be challenging to the pharmaceutical industry 
(Fibiger, 2012; Millan et al., 2016). 
1.4 Research questions, hypotheses, and goals 
The function of myosin XVI has begun to unravel, but many aspects of this myosin are still obscure. 
As described, several functions have been designated to it, but the publications are sparse and 
incoherent. This fact, together with the evidence that myosin XVI may play a role in ASD and 
schizophrenia, calls for elucidation of the very basic characteristics of myosin XVI to obtain a clearer 
picture of its function and biological relevance. 
This Master’s Thesis aimed to clarify the subcellular localization of myosin XVI. Where does myosin 
XVI localize in the cell? Does it co-localize with F-actin? These questions remain partly open in the 
current literature as the results from previous studies have been partly inconsistent. In order to 
elucidate this issue, human bone osteosarcoma epithelial (U2OS) cells endogenously expressing 
MYO16, and transfected U2OS cells overexpressing human MYO16B or rat Myo16b, were stained 
with different subcellular markers and imaged by epifluorescence microscopy. The hypothesis was 
that myosin XVI localizes in the cytoplasm and co-localizes with F-actin. These experiments sought 
to establish a better understanding of the localization of myosin XVI and to provide more insight into 
its function.  
This thesis also aimed to clarify the developmental expression pattern of myosin XVI in the brain, 
concentrating on the olfactory bulb, hippocampus, cerebellum, and cerebral cortex. Is myosin XVI 
expressed in all these brain areas? Does the expression level differ between these brain regions and/or 
between developmental stages? According to the current literature, myosin XVI should be expressed 
in these regions, but description of the developmental expression pattern is missing, especially in the 
olfactory bulb. Previous studies suggest that myosin XVI expression and activity is highest in the 
perinatal days. In order to obtain insight into this issue, Myo16+/+ (wild-type) and Myo16-/- (knock-
out) mice of five different postnatal ages – postnatal day 1 (P1, newborn pup), P11 (infant pup), P28 
(juvenile), P56 (young adult), and ~P250 (full-grown adult) – were utilized to perform western 
blotting. The hypothesis was that Myo16 is expressed in all these brain regions, and that the 
expression is higher early in the development. The ambition of these experiments was to determine 
the developmental trajectory of myosin XVI expression in the brain and whether and how myosin 
XVI is expressed in the developmental stages in which ASD and schizophrenia are manifested. 
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The ultimate goal of this Thesis was to enlighten the possible role of myosin XVI in the pathogeneses 
and symptoms of ASD and schizophrenia, with a particular interest in the olfactory bulb, a less studied 
brain structure in the context of neurodevelopmental disorders. Eventually, this research can open up 
new avenues for treatments, enabling development of more effective and targeted therapies for ASD 






2.1 Subcellular localization  
2.1.1 Endogenous expression  
To develop a better understanding of the function of myosin XVI, immunostaining and 
epifluorescence microscopy were employed in the examination of its subcellular localization. 
Endogenous expression of myosin XVI as well as overexpression of myosin XVIB in U2OS cells 
was verified by western blotting (see section 2.2.1 later in Results). First, endogenous expression of 
myosin XVI was studied by staining untransfected cells with four different anti-MYO16 antibodies, 
and the results varied depending on the antibody (Figure 4). Cells stained with MyBioSource anti-
MYO16 displayed diffuse MYO16 localization mainly in the cytoplasm, especially in the perinuclear 
region. Proteintech anti-MYO16 showed MYO16 localization also mainly in the perinuclear region 
where the fluorescence was often enhanced in punctate structures, although not always. A less intense 
signal was also observed diffusely in the nucleus and cytoplasm. Biorbyt anti-MYO16 was found 
diffusely in the nuclei but also less intensely in the perinuclear region. Comparison with the secondary 
antibody control (Alexa Fluor 488 only) indicated that some signal observed with Proteintech and 
Biorbyt anti-MYO16 could be noise, because the secondary antibody showed minor diffuse labeling 
in the nuclei. Staining with Cameron et al.’s anti-MYO16 was very different from the three other 
antibodies, as it was typically restricted to the nuclei. None of the four studied anti-MYO16 antibodies 






Figure 4. Untransfected U2OS cells stained with different anti-MYO16 antibodies (green), an F-actin marker (Alexa 
Fluor 594 phalloidin, red), and a DNA marker (DAPI, cyan), and untransfected U2OS cells stained with only secondary 
antibody (Alexa Fluor 488, green) and DAPI (cyan). Anti-MYO16 from antibodies top to bottom: MyBioSource anti-
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Figure 5. Human EGFP-MYO16B-overexpressing, EGFP-N1-overexpressing, and untransfected U2OS cells stained 
with different anti-MYO16 antibodies, an F-actin marker (Alexa Fluor 594 phalloidin) and a DNA marker (DAPI). A. 
MyBioSource anti-MYO16. B. Proteintech anti-MYO16. C. Cameron et al.’s anti-MYO16. EGFP-MYO16B-
overexpressing cells are indicated with red arrowheads. Scale bars: 30 m. Objective: 63x. 
 
MyBioSource, Proteintech, and Cameron et al.’s anti-MYO16 were selected for further examination 
of the subcellular localization. To determine which of these antibodies, if any, was most reliably 
recognizing MYO16, transfected U2OS cells were stained with each antibody and co-localization of 
overexpressed MYO16 and anti-MYO16 staining was investigated (Figure 5). MyBioSource and 
Proteintech anti-MYO16 antibodies clearly recognized MYO16 overexpression, as the signal in 
human EGFP-MYO16B-overexpressing cells was similar to EGFP-MYO16B and also more intense 
than the signal in EGFP-N1-expressing and untransfected cells (Fig. 5A and B). MyBioSource anti-
MYO16 stained EGFP-MYO16B-overexpressing cells similarly than EGFP-N1-expressing and 
untransfected cells, localizing to the cytoplasm (Fig. 5A). Proteintech anti-MYO16 stained EGFP-
MYO16B-overexpressing cells slightly differently than EGFP-N1-expressing and untransfected 
cells, localizing to the cytoplasm or to the cytoplasm and nuclei, respectively (Fig. 5B). Cameron et 
al.’s anti-MYO16 did not recognize MYO16 overexpression as it localized to the nuclei, except for 
rare occasions when the antibody stained also the cytoplasm and co-localized with EGFP-MYO16B 
there (Fig. 5C). Despite these inconsistencies, all these three anti-MYO16 antibodies were chosen for 
closer investigation of the potential localization of MYO16, although the validity of Cameron et al.’s 
anti-MYO16 was questionable in the above experiment, at least in most cases. 
When endogenous expression was examined using MyBioSource anti-MYO16, the anti-MYO16 
displayed diffuse distribution in the cytoplasmic compartment where it was concentrated mainly to 
the perinuclear region (Figure 6). MyBioSource anti-MYO16 also frequently appeared in dots in the 
nucleus (Fig. 6; e.g., 6C). In addition, intense fluorescence signal was detected in the nuclei during 
cell division (Fig. 6E and F). As actin filaments were found principally in the cell periphery near the 
plasma membrane, the results indicated that endogenous MYO16 does not co-localize with F-actin 
(Fig. 6A, B, and D). However, co-localization might be possible during cell division when F-actin is 
also condensed in the nucleus, although this was difficult to confirm as the signals were too bright to 





Figure 6. Untransfected U2OS cells stained with MyBioSource anti-MYO16 antibody (green), an F-actin marker (Alexa 
Fluor 594 phalloidin, red), and a DNA marker (DAPI, cyan). Scale bars: 30 m. Objective: 63x. According to 
MyBioSource anti-MYO16, MYO16 is principally perinuclear (A–F). It sometimes appears in dots in the nuclei (C, white 
arrowheads), and might be also nuclear during cell division (E and F, dividing cells are denoted by white arrowheads), 











Figure 7. Untransfected U2OS cells stained with Proteintech anti-MYO16 antibody (green), an F-actin marker (Alexa 
Fluor 594 phalloidin, red), and a DNA marker (DAPI, cyan). Scale bars: 30 m. Objective: 63x. According to Proteintech 
anti-MYO16, MYO16 is found quite diffusely in both the cytoplasm and in the nuclei (A–F). However, it is sometimes 
concentrated to the perinuclear region in a punctate manner (A–C, the puncta are denoted by white arrowheads). It may 
also appear in the nuclei during cell division and co-localize with F-actin there (E and F, dividing cells are denoted by 










Next, endogenous expression was examined using Proteintech anti-MYO16 (Figure 7). Proteintech 
anti-MYO16 displayed localization both in the cytoplasm and in the nucleus (Fig. 7; e.g., 7A). The 
fluorescence signal was typically most intense in the perinuclear region where it often appeared 
punctate (Fig. 7A–C). Sometimes the signal was however more diffuse and detected more widely in 
the cytoplasm (Fig. 7D). Different localization was again observed during cell division, when 
Proteintech anti-MYO16 was detected also in the nuclei (Fig. 7E and F). No apparent co-localization 
with F-actin was observed, but anti-MYO16 possibly co-localized with F-actin during cell division.  
The third antibody, Cameron et al.’s anti-MYO16, revealed disctinctively different localization 
pattern than the two other anti-MYO16 antibodies (Figure 8). Cameron et al.’s anti-MYO16 was 
mostly restricted to the nucleus where the staining was diffuse and covered almost the whole nucleus, 
excluding some non-fluorescent spots that are likely the nucleoli (Fig. 8; e.g., 8A and B). 
Occasionally, Cameron et al.’s anti-MYO16 was detected in the cytoplasm as well (Fig. 8C and D). 
This seemed to occur during cell division (Fig. 7E). Cytoplasmic distribution was however not 
exclusive during cell division, as strong signal was also sometimes detected in the nuclei (Fig. 7F). 
Again, the anti-MYO16 only co-localized with F-actin potentially during cell division. 
In summary, MyBioSource and Proteintech anti-MYO16 antibodies indicated that endogenous 
myosin XVI is generally cytoplasmic and usually enhanced in the perinuclear region, whereas 
Cameron et al.’s anti-MYO16 antibody suggested that myosin XVI is generally nuclear. However, 





Figure 8. Untransfected U2OS cells stained with Cameron et al.’s anti-MYO16 antibody (green), an F-actin marker 
(Alexa Fluor 594 phalloidin, red), and a DNA marker (DAPI, cyan). Scale bars: 30 m. Objective: 63x. According to 
Cameron et al.’s anti-MYO16, MYO16 is mainly nuclear and does not co-localize with F-actin (A–F). However, it 
sometimes appears in the cytoplasm well (C and D). During cell division, it may localize principally in the cytoplasm and 













2.1.2 Overexpression  
Overexpression of myosin XVIB was studied using transfected U2OS cells stained with different 
subcellular markers. Transfection was successful, although transfection efficiency of human 
MYO16B-EGFP and rat Myo16b-EGFP was not as high as desired. This was likely due to the 
relatively large size of human pEGFP-MYO16B and rat pEGFP-Myo16b plasmids, both comprising 
around 240 kDa in protein size. Despite optimization of the Lipofectamine transfection protocol, 
many of the cells transfected with human MYO16B or rat Myo16b did not survive transfection. In 
addition to the transfection itself, this might indicate that overexpression of myosin XVIB is harmful 
to cells. Furthermore, dividing cells were less common among MYO16B/Myo16b-overexpressing 
cells than in untransfected cells, indicating that overexpression of myosin XVIB may cause problems 
in cell division. 
Human EGFP-MYO16B and rat EGFP-Myo16b localized similarly in the U2OS cells; both 
distributed rather diffusely in the cytoplasm, concentrating most intensely in the perinuclear region 
and gradually decreasing in intensity towards the cell periphery (Figure 9). Cells expressing only 





Figure 9. Overexpression of human EGFP-MYO16B, rat EGFP-Myo16b, and EGFP-N1 (positive transfection control) 
(green) in U2OS cells, and untransfected U2OS cells (non-treated control). The cells are stained with an F-actin marker 
(Alexa Fluor 594 phalloidin, red) and a DNA marker (DAPI, cyan) Scale bars: 20 m. Objective: 63x. 
 
A closer look at the subcellular localization of human EGFP-MYO16B, examined together with F-
actin, revealed that EGFP-MYO16B localizes principally to the perinuclear region where F-actin is 
less abundant (Figure 10). Whereas actin filaments are most prevalent in the cell periphery where 
they are arranged vertically and horizontally in relation to the plasma membrane, EGFP-MYO16B 
was mostly detected perinuclearly (Fig. 10; e.g., 10F). In some occasions, however, EGFP-MYO16B 
was concentrated in some regions of the plasma membrane where it also appeared to co-localize with 
F-actin more clearly (Fig. 10A–C). These regions often resembled leading lamellipodia, but 
sometimes also retracting areas. Human MYO16-EGFP-overexpressing cells also seemed to be 






































especially motile, having large lamellipodia. EGFP-MYO16B generally displayed a fine punctate 
distribution pattern, but sometimes larger fluorescent aggregates that co-localized with F-actin were 
also seen (Fig. 10; e.g., 10E–G). These puncta could be vesicles or accumulated actin fibers, 
respectively. Moreover, EGFP-MYO16B was occasionally co-localized with F-actin in dots adjacent 
to or in the nucleus (Fig.  10D and H). These structures could be centrioles that are the main type of 
microtubule organizing centers (MTOCs) in cells. Additionally, increased fluorescence was 
sometimes observed between dividing cells, and it seemed that overexpression might disturb 
cytokinesis, perhaps by causing problems in squeezing the contractile ring between dividing cells 
(Fig. 10B).  
 
Figure 10. Human EGFP-MYO16B overexpression (green) in U2OS cells stained with an F-actin marker (Alexa Fluor 
594 phalloidin, red). Scale bars: 20 m. Objectives: 63x and 100x. EGFP-MYO16B appears to be distributed quite 
diffusely in small puncta in the cell (A–H). It is usually mostly concentrated to the perinuclear region where F-actin is 
less abundant (A, B, and F). It is sometimes found on the plasma membrane where clear co-localization with F-actin is 
observed (A–C, white arrowheads). Additionally, it may localize to larger or smaller cytoplasmic puncta that also co-
localize with F-actin (E and F, white arrowheads), and is occasionally also found in dots adjacent to the nuclei (D, white 
arrowheads). 
 
Similar to human EGFP-MYO16B-overexpressing cells, rat EGFP-Myo16b was also found 
principally in the regions where F-actin is less prevalent (Figure 11). Rat EGFP-Myo16b was most 
intense in the perinuclear region of the cytoplasm (Fig. 11A, E, and G). Similar to human EGFP-












MYO16B, rat EGFP-Myo16b was occasionally condensed in the plasma membrane on areas that 
were likely associated with membrane protrusion and migration, and there EGFP-Myo16b also 
overlapped with F-actin (Fig. 11A–D and H). The pattern of distribution was usually punctate, 
displaying fine-grained granules dispersed in the cytoplasm (Fig.11; e.g., 11G). As human EGFP-
MYO16B, also rat EGFP-Myo16b was sometimes also observed in larger puncta, sometimes not 
overlapping with F-actin but sometimes co-localizing with it (Fig. 11E, F, and H). 
 
Figure 11. Rat EGFP-Myo16b overexpression (green) in U2OS cells stained with an F-actin marker (Alexa Fluor 594 
phalloidin, red). Scale bars: 20 m. Objectives: 63x and 100x. EGFP-Myo16b appears to be distributed rather diffusely 
in the cell (A–H). It often appears in the perinuclear region where F-actin is less abundant (A). It is sometimes found on 
the plasma membrane where it co-localizes with F-actin in membrane protrusions (B–D, white arrowheads). In addition, 
it localizes to larger cytoplasmic puncta that do not co-localize with F-actin (E and F, white arrowheads) or to smaller 
cytoplasmic puncta that co-localize with F-actin (G and H, white arrowheads). 
 
 
To address whether the perinuclear distribution of myosin XVI overlaps with the endoplasmic 
reticulum (ER), transfected cells were stained with an ER marker, protein disulfide-isomerase (PDI) 
antibody (Figure 12). Both human EGFP-MYO16B and rat EGFP-Myo16b co-localized with some 
parts of the ER, and the EGFP signal was most intense in areas where the anti-PDI signal also 
appeared most intense (Fig. 12A–C).  









EGFP-Myo16b (rat) EGFP-Myo16b (rat)
 
 28 
To explore further the fluorescent dots observed adjacent to the nuclei of EGFP-MYO16B-
overexpressing U2OS cells, the cells were stained with an MTOC marker; -tubulin antibody (Figure 
13). This staining showed that EGFP-MYO16B may be localized to the centrosome, the major 
MTOC, in some occasions (Fig. 13A–C). However, this staining was not fully successful for the anti-
-tubulin antibody, or then the antibody did not work ideally, based on the rather dim labeling of the 
centrioles and diffuse signal also elsewhere in the cell. This was likely not related to 
MYO16B/Myo16b overexpression either, as similar staining was observed in untransfected cells. 
 
Figure 12. Co-localization of myosin XVIB and the endoplasmic reticulum (ER) in U2OS cells. A and B: Human EGFP-
MYO16B overexpression (green) stained with an ER marker (anti-PDI, magenta). C: Rat EGFP-Myo16b overexpression 
stained with an anti-PDI. D: EGFP-N1 overexpression stained with an anti-PDI (positive transfection control). E: 
Untransfected cells stained with anti-PDI (non-treated control). F: Human EGFP-MYO16B overexpression stained with 









































































Figure 13. Co-localization of myosin XVI and microtubule organizing centers (MTOCs) in U2OS cells. A-C: Human 
EGFP-MYO16B overexpression (green) stained with an MTOC marker (anti--tubulin, cyan). D: EGFP-N1 
overexpression stained with an anti--tubulin (positive transfection control). E: Untransfected cells stained with anti--
tubulin (non-treated control). F: Human EGFP-MYO16B overexpression stained with only secondary antibody (Alexa 
Fluor 647) (only secondary control). Scale bars: 20 m. Objective: 63x.  
 
In summary, overexpressed myosin XVIB localized mainly to the perinuclear region in U2OS cells. 
This distribution pattern and the localization of the endoplasmic reticulum were overlapping. The 
largely differential localization of F-actin implies that myosin XVIB does not widely interact with it, 
however occasional enhancement of myosin XVIB in the plasma membrane and the concurrent co-
localization with F-actin suggest that myosin XVIB could interact with actin there, for example in 
lamellipodia. Moreover, myosin XVIB sometimes co-localized with F-actin in cytoplasmic puncta, 
possibly vesicles, indicating interaction there as well. Sometimes myosin XVIB appeared in dots 
adjacent to the nuclei, and these could be centrioles. 
Localization pattern between overexpression and endogenous expression was partly consistent when 
comparing overexpression to endogenous expression studied with MyBioSource and Proteintech 
anti-MYO16 antibodies. In this case, both endogenous expression and overexpression were detected 
principally in the perinuclear region, although overexpression was also observed in other areas in the 
cell. However, if Cameron et al.’s anti-MYO16 is included in the comparison, the results from 
overexpression and endogenous expression become inconsistent as this anti-MYO16 was mainly 






































































2.2 Western blotting 
2.2.1 Cell and mouse model validation and antibody selection 
Western blotting was performed to confirm the expression of myosin XVI. First, expression of 
myosin XVI in U2OS cells and in Myo16 wild-type but not knock-out mice was verified. In addition, 
different anti-MYO16 antibodies were tested and the best one selected for subsequent western 
blotting experiments.  
 
Figure 14. Confirming overexpression and endogenous expression of myosin XVI in U2OS cells and confirming Myo16 
expression in P242 Myo16 wild-type (Myo16+/+) and knock-out (Myo16-/-) mouse cerebellum. P, postnatal day. 
Membranes with U2OS cell lysates were first incubated with Proteintech anti-MYO16, then stripped and incubated with 
anti-GFP (note: the size of EGFP-N1 is around 30 kDa and is not visible here). Membranes with mouse cerebellum 
homogenates were incubated with Proteintech anti-MYO16. U2OS cell lysates: 25 g/well, mouse P242 cerebellum 
homogenates: 20 g/well. Cell lysates were loaded in the same gel but presented here separately as the 
chemiluminescence detection time was different in Proteintech anti-MYO16 (the cells overexpressing myosin XVIB were 
overexposed quickly before the bands were visible in the cells endogenously expressing myosin XVI). Myosin XVIB 
bands are denoted by red arrowheads. 
 
Western blotting for U2OS cell lysates and mouse brain homogenates firstly confirmed that 
Proteintech anti-MYO16 antibody recognizes myosin XVI, at least in this application (Figure 14). 
This experiment also confirmed that cells transfected with human pEGFP-MYO16B and rat pEGFP-
Myo16b were overexpressing human EGFP-MYO16B and rat EGFP-Myo16b, respectively, as strong 
bands of around 250 kDa were detected in those lanes. In addition, the cells transfected with pEGFP-
N1 and the untransfected cells were expressing MYO16B endogenously; bands of around 240 kDa 
were visible, though rather dim. Lastly, this experiment confirmed that Myo16b is expressed in 



















































































type mouse cerebellum but absent in knock-out cerebellum. These results verified that the U2OS cell 
line is suitable for studying endogenous as well as overexpression of myosin XVI, though the 
endogenous expression level may be quite low, and also confirmed the validity of the mouse model. 
 
Figure 15. Comparison of Proteintech and MyBioSource anti-MYO16 antibodies in western blotting using P248, P154, 
and P56 Myo16 wild-type (Myo16+/+) and knock-out (Myo16-/-) mouse cerebellum samples. P, postnatal day. P248 and 
P154 cerebellum samples were first incubated with MyBioSource anti-MYO16 and then with Proteintech anti-MYO16, 
P56 cerebellum samples were first incubated with Proteintech anti-MYO16 and then with MyBioSource anti-MYO16. 
P248 and P154 cerebellum homogenates: 50 g/well, P154 cerebellum homogenates: 20 g/well. Myo16b bands are 
denoted by red arrowheads. 
 
MyBioSource, Proteintech, and Cameron et al’s anti-MYO16 antibodies were tested for western 
blotting. Cameron et al.’s anti-MYO16 was first excluded because we did not have much of it nor did 
it work as bands appeared also in knock-out mice. Results of MyBioSource and Proteintech anti-
MYO16 showed that Proteintech anti-MYO16 was better applicable for western blotting; in the blots 
incubated with Proteintech anti-MYO16, bands were correctly visible in Myo16 wild-type but not in 
knock-out mice, whereas incubation with MyBioSource anti-MYO16 resulted in bands present in 
both wild-type and knock-out animals (Figure 15). Therefore, the Proteintech anti-MYO16 was 
selected for subsequent western blotting experiments. Unfortunately, Proteintech anti-MYO16 
appeared to be quite unspecific especially in blots with samples from younger mice. The knock-out 
model proved to be a very important control to distinguish the protein band of interest. The additional 
bands were similarly present in wild-type and knock-out mice, indicating that they were not 
degradation products of Myo16b. According to the UniProtKB/Swiss-Prot database, mice may 
express another XVI isoform of around 200 kDa, however bands of this size were not observed in the 
blots. Non-specificity also led to another problem; gel electrophoresis needed to be run longer in 
order to separate Myo16 bands from unspecific bands of around the same molecular size, which 
resulted in proteins below 75 kDa to be moved out of the gel. As a consequence, common loading 





























































































































expression in the examined tissues was not clear, and gradient gels were also not readily available. 
This lack of loading control limited the quantifiability of myosin XVI expression. However, Myo16 
band and total protein signals in each lane were measured and the Myo16–total protein ratio 
calculated in order to strengthen the reliability of results.  
2.2.2 Myo16b expression in the olfactory bulb, hippocampus, cerebellum, and cerebral cortex 
First, the expression of Myo16b in the mouse olfactory bulb, hippocampus, cerebellum, and the 
cerebral cortex was studied using wild-type (Myo16+/+) and knock-out (Myo16-/-) mice of five 
different ages: P1 (newborn pup), P11 (infant pup), P28 (juvenile), P56 (young adult), and P245 (full-
grown adult) (Figure 16). The results confirmed that Myo16b is expressed in all these brain regions 
in all the studied ages. However, the expression was not uniform over the different regions. At P1, 
Myo16b appeared to be equally expressed in the olfactory bulb, hippocampus, and cerebellum. The 
expression in the cerebral cortex was lower compared to other regions. At P11, Myo16b seemed to 
be equally expressed in the olfactory bulb, cerebellum, and cerebral cortex, but was possibly less 
expressed in the hippocampus. Expression in the olfactory bulb may be slightly higher than 
expression in the cerebellum and cortex. At P28, Myo16b expression appeared to be highest in the 
olfactory bulb, second-highest in the cortex, and equally low in the hippocampus and cerebellum. At 
P56 and P245, Myo16b expression was highest in the olfactory bulb and clearly lower in the other 
regions. Lack of loading control limits the drawing of definitive conclusions, but the comparably high 





Figure 16. Myo16b expression in wild-type (Myo16+/+) and knock-out (Myo16-/-) mice in the olfactory bulb, 
hippocampus, cerebellum, and cerebral cortex at P1, P11, P28 (female), P56 (male), and P245 (female). P, postnatal day. 
P1: 10 g/well. P11 and P28: 15 g/well. P56 and P245: 15 g/well. Samples from the same wild-type and knock-out 
mice were used for each brain region at each time point, and the wild-type and knock-out mice at each time point were 
from the same litter (identity numbers marked in white). Gels with total protein presented on the right. Myo16b bands are 
denoted by red arrowheads.  
 
When Myo16b expression at P1 was compared between several wild-type animals, the expression 
seemed to vary between individuals in some regions (Figure 17). In the cerebral cortex, the 
expression was either considerably lower, little lower, or equal to the expression observed in the other 
regions (Fig. 17A). The expression was more equal in the olfactory bulb, hippocampus, and 
cerebellum (Fig. 17A), although some results also suggested that the expression in the olfactory bulb 





Figure 17. Myo16b expression at P1. A. Myo16 expression in the P1 olfactory bulb, hippocampus, cerebellum, and 
cerebral cortex. P, postnatal day. A knock-out (Myo16-/-) mouse as a control and three wild-type (Myo16+/+) mice 
expressing Myo16, 10 g/well. Samples from the same wild-type and knock-out mice are used for each brain region in 
the same order (hippocampus from the last wild-type missing). B. Myo16 expression in the P1 olfactory bulb, 5 g/well. 
Myo16b bands are denoted by red arrowheads. Identity numbers are marked below each lane.  
 
To explore how the expression of myosin XVIB might change during the postnatal brain 
development, Myo16b expression in P1, P11, P28, and P56 wild-type mice was examined in the 
olfactory bulb, hippocampus, cerebellum, and cerebral cortex (Figure 18). Here, total protein and 
Myo16b band quantification were performed (Fig. 18B) in order to obtain more reliable results, and 
additionally the Myo16b–total protein ratio was calculated (Fig. 18C). This quantification appeared 
necessary, because the total protein was not always equal between the lanes. The results were largely 
consistent with those presented in Figures 16 and 17, indicating a more stable Myo16b expression in 
the olfactory bulb compared to the other regions (Fig. 18A and C). There might, however, be a 
temporary decline in Myo16b expression at P28, and the expression may even be higher in adult than 
in infant mice (Fig. 18C). In the hippocampus, Myo16b expression at P1 and P11 was variable, being 
high in some P1 and P11 mice but lower in others, however low expression at P28 and P56 was a 
consistent finding (Fig. 18A and C). Overall, it seems that the expression tends to be higher in infant 
mice than in juvenile and adult mice (Fig. 18C). In the cerebellum and cortex, Myo16b expression 
was higher at P1 and P11 compared to P28 and P56, indicating a higher expression early in 
development and a subsequent decline (Fig. 18A and C). This difference was however smaller in the 






Figure 18. Developmental expression pattern of Myo16b in mouse olfactory bulb, hippocampus, cerebellum, and cerebral 
cortex. A. Expression of Myo16b in wild-type (Myo16+/+) olfactory bulb, hippocampus, cerebellum, and the cerebral 
cortex at P1, P11, P28 (male), and P56 (male). P, postnatal day. Olfactory bulb: 15 g/well. Hippocampus, cerebellum, 
and cerebral cortex: 20 g/well. Gels with total protein presented on the right. Except for P1 olfactory bulb, samples from 
the same wild-type pairs are used for each developmental time point in each brain region (identity numbers marked in 
white). Myo16b bands are denoted by red arrowheads. B. Comparison of total protein (blue) and Myo16b (orange) signals 
in each sample (the samples are numbered from 1–8 but are in the same order as in A). C. Myo16b–total protein ratio in 
each sample (the samples are numbered from 1–8 but are in the same order as in A).  
 
Some results not presented here indicated that there might be differences in Myo16b expression 
between male and female mice. The sex of pups (P1 and P11 animals) was not determined due to 
methodological issues, but the sex of the older animals (P28, P56, and ~P250) was known. It is worth 
noticing that the differing results observed between P1 and P11 animals could be due to sex 
differences although this was not possible to be examined here.  
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3.1 Subcellular localization of myosin XVI 
The first aim of this Master’s Thesis project was to elucidate the subcellular localization of myosin 
XVI. Co-localization with F-actin was of particular interest. To illuminate this, both endogenous 
expression and overexpression of myosin XVI were explored in U2OS cells. The hypothesis was that 
myosin XVI localizes in the cytoplasm and co-localizes with F-actin. 
With respect to endogenous expression, MyBioSource and Proteintech anti-MYO16 antibodies 
displayed MYO16 localization mainly in the cytoplasm and often concentrated to the perinuclear 
region. Human EGFP-MYO16B and rat EGFP-Myo16b overexpression also distributed in the 
cytoplasm and concentrated principally to the perinuclear region where overexpression partly 
overlapped with the ER. Enhanced fluorescence was also detected in small cytoplasmic puncta, where 
it often overlapped F-actin. In addition, Proteintech anti-MYO16 was frequently accumulated in a 
punctate manner to the perinuclear region. In line with these results, previous studies have observed 
myosin XVI in the neuronal cytoplasm in a punctate manner (Patel et al., 2001), and human and rat 
myosin XVIB overexpression in the cytoplasm distributing either diffusely throughout it or to the 
perinuclear region in a punctate fashion (Cameron et al., 2007). Although the perinuclear region is 
not the primary site of F-actin, it is present there (Svitkina, 2018). The perinuclear region is one site 
of the endomembrane system, a dynamic set of interconnected cytoplasmic membranes that together 
function as an intracellular transportation machinery between the nucleus and the plasma membrane 
(Dacks et al., 2009). In eukaryotes, the main components of the endomembrane system are the nuclear 
membrane, rough and smooth ER, Golgi apparatus, lysosomes, endosomes, vesicles, and the plasma 
membrane (Dacks et al., 2009). The Arp2/3 complex is known to be localize to the endomembrane 
system as well (Goley and Welch, 2006). Therefore, it is not too far-fetched to hypothesize that also 
myosin XVI, a regulator of the Arp2/3 complex, may operate in the endomembrane system and 
contribute to vesicle traffic, for instance. Supporting this idea, myosin XVI has been described to 
localize in vesicles in SH-SY5Y cells (The Human Protein Atlas), and one study has found that 
myosin XVI is important for the number of synaptic vesicles in neurons (Roesler et al., 2019). Several 
other myosins are also known to localize in different parts of the endomembrane system and interact 
with actin there (Hartman and Spudich, 2012). For example, myosin VA appears to be important for 
recycling of endosomes in neurons, and VB transports the ER to dendritic spines in cerebellar 
Purkinje cells (Wagner et al., 2011; Wang et al., 2008).  
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Moreover, large and intensely fluorescent cytoplasmic aggregates were observed in the cell 
overexpressing myosin XVIB. A previous study has indicated that overexpression of myosin XVI in 
HeLa cells may result in collapsed actin filaments and cause their accumulation in the cytoplasm 
(Yokoyama et al., 2011). The observed aggregates might be these, indicating that overexpression of 
myosin XVI can lead to disturbances in the organization of cytoplasmic actin filaments. 
In the current study, overexpression of myosin XVIB was also observed in some regions of the plasma 
membrane where it often co-localized with F-actin. These regions often resembled lamellipodia but 
also retracting areas. Myosin XVIB has been detected in the underlying surface of the plasma 
membrane also in neurons (Patel et al., 2001) and the myosin XVIB tail domain has also been detected 
in lamellipodia and filopodia in COS-7 cells (Cameron et al., 2007). The Arp2/3 complex is also 
present there, regulating the reorganization of lamellipodia, for example (Goley and Welch, 2006). 
This indicates that myosin XVIB has an associated role there as well. Formation of membrane 
protrusions is crucial for cell migration, morphogenesis, and neurite outgrowth, as well as for the 
formation of synapses and dendritic spines (Flynn, 2013). Previously, myosin XVI has been 
implicated in all of these functions (Patel et al., 2001; Roesler et al., 2019; Yokoyama et al., 2011).  
Intense fluorescence was also sometimes detected in puncta adjacent to, or inside, the nuclei when 
myosin XVIB was overexpressed. Interestingly, the results also indicated that myosin XVIB 
overexpression may disturb cell division. MyBioSource anti-MYO16 also occasionally appeared in 
nuclear dots. The observed dots could be centrioles, based on the staining with anti--tubulin. 
Centrioles form the centrosome, an organelle found close to the nucleus (Sanchez and Feldman, 
2017). The centrosome is essential for the alignment of chromosomes during cell division, for 
example, and for progression of the cell cycle (Sanchez and Feldman, 2017). Although the main 
component of the centrosome is tubulin, also actin is associated with it (Rosenblatt et al., 2004). 
Interestingly, also the Arp2/3 complex possibly transiently localizes to the centrosome during the 
interphase (Hubert et al., 2011). It is therefore possible that myosin XVI regulates centrosomal 
function. Myosins II and V are also known to associate with the centrosome (Espreafico et al., 1998; 
Rosenblatt et al., 2004).  
There is also evidence that myosin XVI plays a role in cell cycle progression inside the nucleus. 
Earlier studies suggest that is required for completion of the interphase before the cell can continue 
to cell division (Cameron et al., 2007; Cameron et al., 2013). This is supported by the findings that 
1) Myo16 is nuclear during interphase but both nuclear and cytoplasmic during cell division, 2) the 
expression level of Myo16 is higher during interphase and reduced during cell division, 3) Myo16-
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deficient cells exhibit abnormal morphology as well as features characteristic to apoptosis, and 4) 
overexpression of Myo16b suppresses cell proliferation (Cameron et al., 2007; Cameron et al., 2013). 
Not surprisingly, Cameron et al.’s anti-MYO16 – the same one used to arrive at the above-listed 
conclusions – suggested a major localization to the nucleus and partial spreading to the cytoplasm 
during cell division in the present study. MyBioSource and Proteintech anti-MYO16 antibodies also 
seemed to localize to the nucleus during cell division despite their principal localization to the 
cytoplasm. Previously, in addition to their cytoplasmic locations, human and rat myosin XVIB 
overexpression have been observed also in the nucleoplasm – distributing either uniformly or in 
puncta (Cameron et al., 2007) – a finding not replicated in in this study. The precise molecular 
mechanisms behind the alternating locations of myosin XVI are currently unclear, however. The C-
terminal tail domain of myosin XVIB contains an NLS sequence and is considered to mediate 
localization to the nucleus, whereas the N-terminal pre-motor domain contains an NES sequence and 
could therefore mediate localization to the cytoplasm (Cameron et al., 2007). Although F-actin is 
principally found in the cytoplasm, it is also present in the nucleus, at least transiently during cell 
division, indicating that myosins may interact with F-actin there as well (Baarlink, 2017).  
The localization of myosin XVI is likely dependent on the phase of the cell cycle, but the observed 
locations of endogenous expression may also be influenced by other factors. First, post-translational 
modifications could affect antibody binding. For example, Cameron et al.’s anti-MYO16 could 
recognize MYO16 when it is modified to a form present in the nucleus. Second, non-specificity of 
the antibodies is always a concern. Unfortunately, the anti-MYO16 antibodies used in the current 
study were not completely specific to myosin XVI in western blotting, which indicates the same in 
staining. Finally, although myosin XVIA isoform should be expressed less than the XVIB isoform in 
the body, it is also likely present in smaller quantities, and the antibodies possibly tagged it as well.  
All the anti-MYO16 antibodies used in this study bound N-terminal sequences not specific to myosin 
XVIB; MyBioSource and Cameron et al.’s anti-MYO16 tagged sequences from the motor domain 
and Proteintech anti-MYO16 a sequence from the pre-motor domain. However, myosin XVIA has 
been reported to localize to the cytoplasm only and concentrate to the perinuclear region similarly to 
myosin XVIB there (Cameron et al., 2007). Expressing N- and C-termini of myosin XVI separately 
might however help to elucidate the differing locations. 
The present results of subcellular localization of myosin XVI are summarized in Figure 19. Whether 
the observed locations are reproducible in other cell types, such as in neurons, remains a question that 
future studies need to answer. Obtaining a consistent understanding of the subcellular localization of 
 
 39 
myosin XVI – whether nuclear, cytoplasmic, or both, and whether dependent on the cell type – will 
further clarify its function and biological significance. The possible role of myosin XVI in cell 
division and cell migration could be studied using live cell imaging. Exploring co-localization with 
the PI3K, WRC complex, and Arp2/3 complex, for example, would possibly enable more solid 
conclusions of the cellular mechanisms and function of myosin XVIB.  
 
 
Figure 19. Graphical summary of subcellular localization results and proposed functions for myosin XVI.  
 
3.2 Myo16b expression in the brain 
The second aim of this Master’s Thesis was to study Myo16 expression in different regions of the 
mouse brain, and to elucidate the expression trajectory of myosin XVI during postnatal brain 
development. The hypothesis was that Myo16b is expressed in all the studied regions, but we 
expected that the expression is highest at P1 and gradually decreased in later stages.  
Western blotting confirmed that Myo16b is expressed in the olfactory bulb, hippocampus, 
cerebellum, and cerebral cortex from newborn to full-grown adult mice. This finding was aligned 
with earlier reports that have confirmed the presence of Myo16 mRNA and protein in these areas in 
young rodents (Patel et al., 2001; Yokoyama et al., 2011). This study confirmed that Myo16b is 
expressed also in older adult mice.  
With respect to the hippocampus, cerebellum, and cortex the present results also indicated a higher 
Myo16b expression in P1 and P11 pups compared to juveniles (P28) and young adults (P56). The 
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developmental expression pattern in the olfactory bulb was an exception, showing more stable 
Myo16b expression also after the early postnatal days. Myosin XVI expression is reportedly highest 
during the early postnatal days (Patel et al., 2001; Yokoyama et al., 2011). For example, the level of 
Myo16 mRNA expression in rat cerebellum and cortex peaks during the first and second postnatal 
weeks (Patel et al., 2001). Interestingly, phosphorylation of the tyrosine residues of mouse Myo16b 
begins in the embryonic period, peaks during the perinatal days, then gradually decreases, and is 
significantly lower in adult animals (Yokoyama et al., 2011). This suggests that myosin XVIB is most 
active during this period, at least in respect to activation of the PI3K–WRC–Arp2/3 pathway and 
consequent branched actin formation that are assumedly triggered by phosphorylation of myosin 
XVIB (Yokoyama et al., 2011). Next, it would be interesting to determine the phosphorylation state 
of Myo16b from the blots of this study as phosphatase inhibitors were used in all samples. 
The specific functions of myosin XVI in the developing brain remain elusive. Yokoyama et al. (2011) 
found that mouse Myo16 localizes to developing cortical neurons during the embryonic period. In 
P10 rat brain, Myo16b localizes to migrating cerebellar granule neurons (Patel et a., 2001). A recent 
study found that Myo16 localizes to the dendritic spines in the mouse cerebellum (Roesler et al., 
2019). These findings, also supported by the results indicating localization to the plasma membrane 
and vesicles, provide evidence that myosin XVI regulates cell migration and synaptic function. Also 
consistent with these hypotheses, actin cytoskeleton reorganization is crucial for many 
neurodevelopmental processes, such as migration, neurite outgrowth, and formation of synapses and 
dendritic spines (Andersen, 2003; Yokoyama et al., 2011).  
An intriguing finding was the high Myo16b expression in the olfactory bulb in all studied ages, which 
suggests a continuous Myo16b activity there throughout the lifespan. One explanation for this result 
could be mouse olfactory bulb neurogenesis, as mice have ongoing neurogenesis in the olfactory bulb 
(Bergmann et al., 2015). However, postnatal neurogenesis is also present in the hippocampus, both 
in human and mice (Bergmann et al., 2015), but a similar continuously high Myo16 expression was 
not observed there. Could myosin XVI play a special role in the olfactory bulb? Could myosin XVIB, 
for instance, regulate cell division and neurogenesis in the olfactory bulb?  
One thing to consider is the unspecific binding of the antibody that could not be totally eliminated in 
spite of protocol optimization. It seems unlikely that the non-specific bands are only cleavage 
products or post-translational modifications of myosin XVI as those bands appeared also in knock-
out samples. Whether they are different myosin XVI isoforms, different myosins, or something else, 
remains unanswered. With respect to different isoforms, it is known that rat Myo16b is the principal 
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isoform expressed in the body, including both the developing and adult brain (Patel et al., 2001). In 
their study (2001), Patel et al. concluded that Myo16a mRNA expression is minimal compared to 
Myo16b. However, they also observed minor, assumedly Myo16a bands of around 150 kDa in their 
blots when using anti-MYO16 directed against the N-terminus and rat tissue samples. The antibody 
used in the current study was also directed against the N-terminus, suggesting a similar possibility. 
However, mice do not reportedly have the 150 kDa isoform but instead another isoform of around 
200 kDa isoform, which was not observed in the blots. Additional methodological challenges were 
also faced in this study, from mouse reproduction to preparation of samples, running gel 
electrophoresis, and quantifying sample loads. Especially the tiny P1 and P11 dissections from the 
olfactory bulb and hippocampus were challenging to prepare and required adjustments to the protocol. 
Furthermore, only a small amount of final sample could be prepared. The small volume of samples, 
together with a limited number of animals, restricted the number of repetitions that could be 
performed. Myo16 expression was however repeated twice at minimum for each animal, and the 
results presented here were a consistent finding. Future studied will need to perform more quantitative 
analyses of Myo16 expression.  
Finally, some findings proposed that there might be sex-related or other inter-individual differences 
in Myo16b expression. The sex of the youngest animals (P1 and P11) was not determined due to 
methodological issues, however the sex of the older animals was known. This study did not aim to 
explore sex-related differences, but the possibility that they exist cannot be excluded.  
The conclusions drawn from the present results of developmental Myo16b expression pattern are 
summarized in Figure 20. In the future, the cellular distribution of myosin XVI in the examined 
regions, especially in the olfactory bulb, should be studied in greater detail. Initially, the third aim of 
this project was to perform immunohistochemistry in mouse brain in order to elucidate whether 
Myo16 distributes in certain cell types, such as inhibitory interneurons. This would broaden our 
understanding of the function of myosin XVI in the brain. For example, the olfactory bulb is known 
to contain inhibitory neurons and excitatory neurons, and their interplay is considered to be essential 




Figure 20. Graphical summary of the conclusions drawn from the developmental Myo16b expression results. 
 
3.3 Linking the findings to ASD and schizophrenia 
What could the results of this Thesis mean in the context of the human brain and ASD and 
schizophrenia? This study suggests that in the non-affected hippocampus, cerebellum, and cortex, 
there is higher MYO16 expression in early childhood and lower MYO16 expression in adolescence 
and adulthood. Additionally, this study provides evidence that in the non-affected olfactory bulb, 
there is quite stable MYO16 expression from early childhood to adolescence and adulthood. The 
clinical symptoms of ASD usually emerge in early childhood approximately corresponding to mouse 
age P1–P11, whereas the symptoms of schizophrenia typically manifest themselves in adolescence 
or in early adulthood approximately corresponding to mouse ages P28 and P56. Some studies have 
indicated that the expression of MYO16 is lower than normal in the autistic brain and higher than 
normal in the schizophrenic brain (Liu et al., 2015; Rodriguez-Murillo et al., 2014). Could MYO16 
mutations in ASD lead to reduced MYO16 expression in early childhood and MYO16 mutations in 
schizophrenia contrariwise to increased MYO16 expression in adolescence and early adulthood, 
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causing a differential expression trajectory? Consequently, MYO16 expression could be constantly 
too low in ASD and constantly too high in schizophrenia.  
What could the consequences of altered MYO16 expression be at the cellular level? There is no clear 
answer as yet, but we can hypothesize. It has been speculated that MYO16 mutations could contribute 
to the pathogenesis of ASD via altered dendritic spines (Joensuu et al., 2018). Indeed, disruptions in 
the PI3K–WRC–Arp2/3 pathway can lead to structurally deficient spines (Hotulainen et al., 2009; 
Spence et al., 2016). Moreover, F-actin turnover rate may be accelerated in the dendritic spines in the 
absence of MYO16 (Roesler et al., 2019). Abnormal dendritic spines have been implicated in both 
ASD and schizophrenia, and it has been hypothesized that their number is too high in the autistic 
brain and too low in the schizophrenic one (Penzes et al., 2011). The present results propose that one 
subcellular location of MYO16 is the plasma membrane, supporting the possibility that it participates 
in the formation of dendritic spines. Perhaps low MYO16 expression leads to too many dendritic 
spines in ASD and high MYO16 expression leads to too few dendritic spines in schizophrenia.  
The symptoms of ASD and schizophrenia are likely not stemming from abnormalities in some 
specific brain areas but rather from broad neural circuits that extend beyond the boundaries of 
different brain regions. However, it can be hypothesized that the cognitive and social symptoms may 
partly be rooted in altered function of MYO16 in the hippocampus, cortex, and cerebellum, and that 
the olfactory symptoms may, in some extent, be rooted in altered function of MYO16 in the olfactory 
bulb. 
Future studies should also aim to explore the possible sex-related differences in myosin XVI 
expression in the brain. Interestingly, the prevalence of ASD is higher in males compared to females, 
with a ratio of approximately 3:1 (Hodges et al., 2020). 
An important issue to consider here are developmental differences between human and mouse. Basic 
neuroanatomy and fundamental developmental processes are highly similar between these two 
species, but certain aspects are unique to human (Zhao and Bhattacharyya, 2018). For example, 
human neurodevelopment occurs over a longer time course and is characterized by higher complexity 
and specific genetic features (Zhao and Bhattacharyya, 2018). Another example is the olfactory bulb. 
The structure and neuronal count of the olfactory bulb is largely similar between humans and mice 
(McGann, 2017), but unlike mice humans do not display prominent neurogenesis in the olfactory 
bulb (Bergmann et al., 2015). Olfactory bulb neurogenesis is very limited or even absent in human 
adults contrary to most other mammals (Bergmann et al., 2015). This raises a question of whether the 
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current results – in terms of the olfactory bulb – are fully applicable to human. Nevertheless, the 
existence of this difference does not necessarily imply a difference in myosin XVI function in the 
olfactory bulb during early postnatal stages. Despite the fact that certain aspects of human 
neurodevelopment and neurodevelopmental disorders cannot be fully encapsulated in any other 
species, animal models still provide important knowledge that can be attributed to human as well. 
3.4 Significance of the research 
To date, only a handful of articles about myosin XVI have been published. Findings however point 
to its importance in neurodevelopment and role in some cases of ASD and schizophrenia. 
Investigating the localization and expression of myosin XVI is therefore a key for obtaining a better 
insight into how neuronal function and brain development are affected when the expression of myosin 
XVI is altered.  
Neurodevelopmental disorders are extraordinarily complex conditions in terms of pathophysiology, 
which has considerably complicated diagnostics and development of new treatments. Currently, there 
is an unmet medical need in both ASD and schizophrenia. Better understanding of the biological 
underpinnings of these disorders is therefore critical for developing more effective therapies for the 
affected individuals. 
Although ASD and schizophrenia are highly heterogeneous conditions with a multitude of genes 
having been linked to them, the genes can be clustered into fewer functional entities that can also be 
differently affected in different individuals (Duda et al., 2018). Pooling the genetic effects and 
classifying the cases into different subgroups could serve as a basis for development of better 
treatments. For example, identifying when and understanding how MYO16 is affected might be 
beneficial for categorizing the cases of ASD and schizophrenia, and further for developing treatments 
that target similar cases. Most ideally, understanding the developmental expression of proteins 
involved in ASD and SZ could even enable prevention of the progression of these disorders and 
outbreak of symptoms. 
ASD and schizophrenia are two common, persistent, and debilitating conditions that have long 
remained without exact explanations and are still stigmatized in the society. Therefore, understanding 
the biology of ASD and schizophrenia better and moving the science forward around them is 
important for the affected individuals, for their relatives, as well as for the society as a whole. 
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4 Materials and methods 
 
4.1 Fluorescence staining  
4.1.1 Cell culture 
The human bone osteosarcoma epithelial (U2OS) cell line was selected as a model for studying the 
subcellular localization of myosin XVI for several reasons. U2OS cells exhibit a pronounced actin 
cytoskeleton with clear F-actin structures, and the normal cytoskeletal organization of these cells is 
also well known in the group. U2OS cells are relatively flat and have small enough nuclei to 
distinguish cytoplasmic structures. In addition, U2OS were more reliably available than primary cells, 
such as neurons. Furthermore, U2OS cells are more durable, transfectable, and ethically justified than 
primary cells. According to the Human Protein Atlas, U2OS cells express MYO16 mRNA, indicating 
that they are endogenously expressing the protein. 
U2OS cells were obtained as a gift from another research group and stored at -140C. Cell culture 
was created by quickly thawing the cells at 37C and suspending them in 5 ml of pre-warmed 
Dulbecco’s Modified Eagle’s Medium (DMEM) – high glucose (#D6429, Sigma-Aldrich) 
supplemented with 10% fetal bovine serum, 1% L-glutamine and 0.5% penicillin–streptomycin (i.e., 
growth medium). The cells were centrifuged (900 g, 4 min) and the resulting cell pellet resuspended 
in 10 ml of fresh growth medium. The cells were cultured in standard conditions (37C, 5% CO2) on 
standards cell culture dishes (100 x 20 mm, #664 160, Greiner Bio-One) and passaged when they 
were around 70% confluent. Passaging was performed by first washing the cells once with phosphate-
buffered saline (PBS) and adding 1 ml of Trypsin–EDTA solution (#T3924, Sigma-Aldrich). Then 
the cells were incubated in standard conditions (5 min), mixed with 8 ml of fresh growth medium, 
and transferred to a new dish with fresh growth medium in a ratio of about 1:5.  
4.1.2 Plasmid production 
Three different plasmids, tagged with enhanced green fluorescent protein (EGFP), were used in 
transfection of U2OS cells; pEGFP-MYO16B (human, full-length 1858 aa isoform) and pEGFP-
Myo16b (rat, full-length 1912 aa isoform) for examining the subcellular localization of myosin XVIB, 
and pEGFP-N1 for transfection control. Rat pEGFP-Myo16b plasmids was produced by the author 
of this Thesis. Human pEGFP-MYO16B and pEGFP-N1 plasmids were produced earlier by other 
group members, similarly than the rat pEGFP-Myo16b discussed below. 
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Production of rat plasmid DNA was performed using DH5 competent Escherichia coli cells and 
plasmid vectors containing genes for EGFP, kanamycin resistance, and full-length rat Myo16 (20 
ng/l pEGFP-C3-Myo16b). Bacterial transformation was initiated by thawing the bacteria and the 
plasmid vectors on ice. Then the plasmids were mixed with the cells 1:20 in a sterile tube. The 
resulting solution was cooled down on ice (20 min), followed by a quick heat shock (40 sec, at 42C) 
and subsequent cooling on ice (5 min). 500 l of S.O.C. Medium (#15544-034, Invitrogen) was added 
to the solution and the bacteria were cultured in an incubator (1 h, shaking 250 rpm, at 37C). 200 l 
of the culture was placed on a kanamycin plate, air-dried, and incubated again upside-down (18 h, at 
37C). One of the kanamycin-resistant DH5 colonies was picked and mixed with 4 ml of Lysogeny 
broth medium (#T00053, Huslab) containing 25 g/ml kanamycin. The bacteria were cultured (5 h, 
shaking 225 rpm, at 37C), mixed with 200 ml of Lysogeny broth medium containing 50 g/ml 
kanamycin, and cultured once again (18 h, 225 rpm, at 37C). Plasmid DNA was purified using the 
maxiprep method and QIAfilter Plasmid Maxi Kit (25) (#12263, Qiagen), and proceeding as 
instructed in the Qiagen QIAfilter Plasmid Purification Handbook: www.qiagen.com/HB-1169. First, 
the transformed bacteria were centrifuged (30 min, 4600 x g, at 4C) and the resulting pellets 
resuspended in Buffer P1. Buffer P2 was added and the lysates incubated (5 min, at RT), after which 
Buffer P3 was added and the lysates poured into capped QIAfilter Cartridge tubes where the lysates 
were kept for 10 min. Then the tubes were uncapped and placed on equilibrated QIAGEN-tip filter 
tubes through which the lysates were filtered with a plunger. The filter tubes were washed twice with 
Buffer QC and plasmid DNA eluted to new tubes with pre-warmed Buffer QF. Plasmid DNA was 
precipitated by adding 10.5 ml of isopropanol, centrifuging (1 h, 4600 x g, at 4C), diluting the pellets 
in 5 ml of 70% ethanol, and centrifuging again (30 min, 4600 x g, at 4C). The pellets were air-dried 
and dissolved in 200 l of Tris-EDTA buffer (pH 8.0). Finally, concentration of the plasmid DNA 
was measured using NanoDrop One instrument (Thermo Scientific). Final concentration of 1.0 
g/l was obtained by mixing the plasmid DNA solution with Tris-EDTA buffer. The plasmids were 
stored at -20C. 
4.1.3 Lipofectamine transfection 
The U2OS cells were counted and plated in smaller culture plate wells the day before transfection. 
Cover glasses (Ø 13 mm, 0.16 mm, #631-0150, WWR), first stored in 70% ethanol, were placed in 
24-well culture plates (#3524, Corning Costar®) and disinfected in ultraviolet light for 15 min. The 
cells, about 70% confluent, were counted by gently mixing trypsinized cells with fresh growth 
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medium and pipetting the cells to a counting slide (#1450015, Bio-Rad). Cell density was counted 
using TC20™ automated cell counter (#1450102, Bio-Rad). Based on the average result of six 
repeated measurements a final concentration of 40 000 cells/ml (20 000 cells per well) was obtained 
by blending cells and fresh growth medium up to the required volume. The culture plate wells were 
washed twice with PBS, the cells added and then cultured in standards conditions for around 18 h. 
Prior to transfection, the cells were washed with PBS and the normal growth medium was changed 
to medium without antibiotics, followed by 1 h incubation in standards conditions. First, 
Lipofectamine 2000 Reagent (#11668-019, Thermo Scientific) was diluted in DMEM (2 ul 
Lipofectamine + 50 ul DMEM per well) and similarly each plasmid DNA (human pEGFP-MYO16B, 
rat pEGFP-Myo16b, pEGFP-N1) was diluted in DMEM (0.8 ug DNA + 50 ul DMEM per well). 
These solutions were incubated separately for 5 min (at RT) before mixing the Lipofectamine solution 
with each plasmid DNA solution (1:1). The resulting transfection mixes were again incubated (25 
min, at RT), after which 100 l of transfection mix was pipetted dropwise to each well, excluding 
untransfected controls that were otherwise treated similarly to transfected cells. Then the cells were 
incubated in standard conditions for 5 h. Transfection was completed by washing the cells twice with 
PBS and changing to the normal growth medium, and the cells were let to grow in standard conditions 
for around 18 h. The cells were washed twice with PBS and finally fixed by adding 250 l of 4% 
paraformaldehyde in PBS per well, incubating (20 min, at 37C), and washing again twice with PBS. 
The cells were stored in PBS at 4C, with parafilm around, until staining. 
The treatment of untransfected U2OS cells, intended for studying endogenous expression of MYO16, 
was similar to transfected cells, excluding transfection. The cells were similarly plated in 24-well 
plates on coverslips, 40 000 cells/ml (20 000 cells per well) and cultured in standard conditions for 
around 18 h before fixation and storing.  
4.1.4 Staining 
Transfected U2OS cells were stained with Alexa Fluor® 594 phalloidin (#A12381, Invitrogen; F-
actin marker) and PureBlu™ DAPI (#1351303, Bio-Rad; DNA marker). First the cells were washed 
with PBS, permeabilized with 300 μl of 0.5% Triton X-100 in PBS per well (7 min), washed again 
with PBS, and blocked with 300 μl of 3% normal donkey serum (#S2170-100, Biowest) with 0.5% 
bovine serum albumin (BSA) in PBS per well (30 min or longer). Then the cells were incubated with 
25 l of Alexa Fluor 594 phalloidin (1:400 in the blocking solution) (1h, at RT, in darkness). Next, 
the cells were incubated with 25 l of DAPI (1:100 in 0.1% Triton X-100 in PBS) (20 min, at RT, in 
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darkness). The cells were washed with 0.2% BSA in PBS (3 x 10 min, 150 rpm, in darkness) and then 
the coverslips were dipped in mQH2O, gently dried, and mounted on imaging slides (#12372098, 
Thermo Scientific) with 15 l of Shandon™ Immu-Mount™ mounting medium (#9990402, Thermo 
Scientific). The slides were kept at RT overnight before storing them at 4C. 
Untranfected U2OS cells were stained with anti-MYO16 antibodies, Alexa Fluor 594 phalloidin, and 
DAPI. Four different anti-MYO16 antibodies were tested: rabbit polyclonal anti-MYO16 from 
MyBioSource (#MBS9609973), rabbit polyclonal anti-MYO16 from Proteintech (#25104-1-AP), 
rabbit polyclonal anti-MYO16 from Biorbyt (#orb629102), and anti-MYO16 obtained as a gift from 
another research group (described in Cameron et al., 2007). Permeabilization and blocking of the 
cells were carried out as with transfected cells. The cells were then incubated with 25 l of anti-
MYO16 (MyBioSource, Proteintech, and Biorbyt anti-MYO16: 1:200 in the blocking solution; 
Cameron et al.’s anti-MYO16: 1:150 in the blocking solution) (1.5 h, at RT). Then the cells were 
washed with 0.2% BSA in PBS with gently shaking (3 x 10 min, 150 rpm) before incubation with 25 
l of Alexa Fluor® 488 donkey anti-rabbit lgG antibody (#A21206, Invitrogen; secondary antibody) 
and Alexa Fluor 594 phalloidin (1:400 and 1:400 in the blocking solution) (1 h, at RT, in darkness), 
and subsequent incubation with 25 l of DAPI (1:100 in 0.1% Triton X-100 in PBS) (20 min, at RT, 
in darkness). Finally, the cells were washed with 0.2% BSA in PBS (3 x 10 min, 150 rpm, in 
darkness), and mounted and stored as the transfected cells.  
Some of the transfected U2OS cells were also stained with anti-MYO16, Alexa Fluor 594 phalloidin, 
and DAPI to examine whether the antibodies recognize overexpression. This staining was otherwise 
similar to staining of untransfected cells, but Alexa Fluor 488 was replaced with Alexa Fluor® 647 
goat anti-rabbit lgG antibody (#A21244, Invitrogen). Additionally, some of the transfected cells were 
stained with mouse monoclonal anti-PDI antibody (1D3) (#SPA-891, Assay Designs/Stressgen; ER 
marker), Alexa Fluor 594 phalloidin, and DAPI, or mouse monoclonal anti--tubulin (#T6557, 
Sigma-Aldrich; microtubule organizing center (MTOC) marker), Alexa Fluor 594 phalloidin, and 
DAPI. These stainings were otherwise similar to staining of untransfected cells, but anti-MYO16 and 
Alexa Fluor 488 were replaced with anti-PDI (1:200 in the blocking solution) or anti--tubulin 
(1:5000 in the blocking solution) and Alexa Fluor® 647 donkey anti-mouse lgG antibody (#A31571, 
Invitrogen; 1:400 in the blocking solution). 
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Transfection controls were EGFP-N1-expressing U2OS cells (positive transfection control) and 
untransfected U2OS cells (non-treated control). Secondary antibody control was used for the cells 
stained with either anti-MYO16, anti-PDI, or anti--tubulin (Alexa Fluor 488 or Alexa Fluor 647).  
4.1.5 Microscopy 
U2OS cells were imaged at Biomedicum Bioimaging Unit, using Zeiss Axio Imager 2 
epifluorescence microscope with Hamamatsu Orca Flash 4.0 LT camera and Zen Blue software. 63x 
oil and 100x oil objectives were used to reach good resolution. The images were processed using Fiji 
ImageJ software (version 2.1.0/1.53c).  
4.2 Western blotting 
4.2.1 Mice and genotyping 
The mouse cell line was obtained as a generous gift from Wolfgang Wagner and his colleagues 
(described in Roesler et al., 2019). The wild-type mice were C57BL/6J (B6) strain, the Myo16 knock-
out model B6-Myo16em3/J (Myo16-KO-43L). Animals were housed 2–3 mice per cage in a 
controlled environment (temperature 21 ± 1°C, humidity 50 ± 10%, light period 07:00 AM to 7:00 
PM) and supplied with food and water ad libitum. 
Genotyping was performed to select wild-type (Myo16+/+) and knock-out (Myo16-/-) mice for 
western blotting. Thermo Scientific Phire Tissue Direct PCR Master Mix (#F170S) kit was used for 
genotyping the mice. P1 mice were genotyped using tail samples and the older animals using ear 
samples. First, Dilution Buffer and DNARelease Additive were mixed (1:40) and 20 l of the 
resulting mix added to each tissue sample. DNA was extracted using C1000 Touch™ Thermal Cycler 
(Bio-Rad) (program: 2 min at RT, 2 min at 98C, stand by 4C). Phire Tissue direct PCR Master Mix 
(2X), mQH2O and primers (Myo16 forward and reverse; obtained from Wolfgang Wagner’s group) 
were mixed with DNA extraction (8:8:1:1:2) and the DNA amplified (program: initial denaturation, 
98C – 120 sec, denaturation 98C – 10 sec, annealing 68C – 20 sec, extension 72C – 25 sec x35, 
final extension 72C – 300 sec, stand by 4C). 18 l samples and 10 l GeneRuler 100 bp DNA 
Ladder was loaded per well. Agarose gel (1.5% agarose in Tris-acetate-EDTA buffer with 6 l of 
Midori Green Advance DNA stain [#MG04, Nippon Genetics]) electrophoresis was run (30 min, 60 
V) and the bands imaged using ChemiDoc™ Touch Imaging System (Bio-Rad) (Figure 21). Both 
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positive (+/+, -/-, +/-) and negative (mQH2O) controls were used to confirm the results. Myo16 wild-
type and Myo16 knock-out bands were 400 bp and 150 bp, respectively.  
 
 
Figure 21. One of the mouse genotyping gels. Wild-type (Myo16+/+) mice have a 400 bp band, knock-out (Myo16-/-) 
mice have a 150 bp band, and heterozygous (Myo16+/-) mice have both 150 bp and 400 bp bands. C-, negative control 
(mQH2O only). Samples: 18 l, DNA ladder: 10 l. 
 
4.2.2 Preparation and western blotting of mouse brain homogenates  
Mice were sacrificed under Mebunat anesthesia. For P11, P28, P56 and ~P250, the other brain 
hemisphere was dissected to the olfactory bulb, hippocampus, cerebellum and cortex. For P1, both 
hemispheres were dissected in order to have the minimum required amount of tissue for sample 
preparation. The samples were stored without liquid at -80C. These steps were performed by another 
group member. 
Brain samples were thawed and handled on ice. Radioimmunoprecipitation assay buffer (150 mM 
NaCl, 1.0% NP-40, 0.5% Sodium deoxycholate, 50 mM Trizma base, no SDS; pH 8.0) containing 
10% Complete (protease inhibitor cocktail tablets, dissolved in mQH2O, #04693116001, Roche) and 
10% PhosSTOP (phosphatase inhibitor cocktail tablets, dissolved in mQH2O, #04906837001, Roche) 
was added to the samples, ranging from 50–400 l according to the estimated volume of each tissue 
sample. Samples containing 300 l or more of the lysis buffer (~P250: all, P56: all, P28: cortex) were 
transferred into 2 ml soft tissue homogenizing tubes with 1.4 mm ceramic beads (#10032-358, Omni 
International) and homogenized using Bead Ruptor Elite Bead Mill Homogenizer (Omni 
International) with the program for brain tissue (4.85 m/s, 20 sec). After this the homogenates were 
again transferred to new Eppendorf tubes. Samples containing 80–300 l lysis buffer (P28: olfactory 
bulb, hippocampus, cerebellum; P11: hippocampus, cerebellum, cortex; P1: cerebellum, cortex) were 
homogenized manually using Dremel® 3000 multi-tool (3000-15) with a sterilized attachment for 
homogenization (3 x 8 sec at RT, on ice in between). Samples with less than 80 l lysis buffer (P11; 
olfactory bulb; P1: olfactory bulb, hippocampus) were disrupted manually with a needle and by quick 
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vortexing. The samples were centrifuged (15 min, 14 000 rpm, at 4C), followed by collection of 
supernatants to new Eppendorf tubes, adding 1% SDS, and new centrifugation (14 000 rpm, 20 min, 
at 4C). The resulting supernatants were transferred to new Eppendorf tubes prior to protein 
concentration measurement. Protein concentrations were determined using BCA Protein Assay Kit 
(#23227, Thermo Scientific). Blank (mQH2O) standards, BSA standards, and tissue samples were 
diluted in mQH2O (1:9) in 96-well microplates and incubated with BCA Reagent mix (30 min, at 
37C). Absorbances were measured using EnSpire MultiMode Plate Reader (PerkinElmer) and 
protein concentrations calculated from triplicate average values. The final samples for western 
blotting contained either 1.0 mg/ml (P11, P28, P56, ~P250) or 0.50 mg/ml (P1) protein, depending 
on the initial concentrations, in mQH2O and 1x Laemmli buffer (from 4x Laemmli Sample Buffer, 
#161-0747, Bio-Rad). The samples were boiled (5 min, at 100C) and stored at 4C until western 
blotting. 
7.5% stain-free polyacrylamide gels (TGX Stain-Free FastCast Acrylamide kit, #161-0181, Bio-
Rad) were cast for gel electrophoresis. 10–20 g protein per well was loaded for each sample, with 
10 l stained standard proteins (Precision Plus Protein All Blue Standards, #1610373, Bio-Rad) 
and unstained standard proteins (Precision Plus Protein Unstained Protein Standards, #1610363, 
Bio-Rad). The gels were run in Tris-Glycine-SDS buffer on ice, at 200 V for 1 h 45 min and, 
unfortunately, standard proteins below 75 kDa were run out of the gel. This was done because the 
Proteintech anti-MYO16 used in western blotting appeared to bind to several proteins of around the 
same size as Myo16, and this unspecific binding interfered with the detection as the unspecific bands 
overlapped with Myo16 bands. When the gel was run longer, the unspecific bands were more 
separated from Myo16 bands which were then more easily distinguished. 
Gel electrophoresis was followed by the steps described in Trans-Blot Turbo Transfer System 
Instruction Manual: https://www.bio-rad.com/webroot/web/pdf/lsr/literature/10020688.pdf. First, 
the gels were activated using ChemiDoc™ Touch instrument. Protein transfer was performed using 
Trans-Blot Turbo RTA Transfer Kit, LF PVDF (#1704274, Bio-Rad) and Trans-Blot Turbo 
Transfer System (#1704150, Bio-Rad). Polyvinylidene difluoride membranes were first immersed in 
95% ethanol. Then ion reservoir stacks and the membranes were soaked in transfer buffer (with 1x 
Transfer Buffer and 20% ethanol in mQH2O) for a few minutes and assembled into a transfer pack. 
Protein transfer was run using Trans-Blot Turbo (Bio-Rad) and the program for high molecular 
weight proteins (25 V for 10 min). After transfer, the membranes were soaked first in mQH2O, then 
in 70% ethanol, and activated using ChemiDoc™ Touch. The membranes were blocked in 5% milk 
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in Tris-buffered saline with 0.1% Tween® 20 (TBST) (1 h, shaking, at RT) and incubated with the 
primary antibody (1:1000 Proteintech anti-MYO16 (#25104-1-AP) in 5% milk and TBST, with 
0.02% sodium azide) (around 18 h, shaking, at 4C). The membranes were washed in TBST (5 x 6 
min, shaking, at RT), incubated with the secondary antibody (1:10 000 HRP-conjugated mouse anti-
rabbit lgG antibody [#211-032-171, Jackson Immunoresearch]) in 5% milk and TBST) (1 h, shaking, 
at RT), washed again in TBST (3 x 10 min, shaking, at RT), and finally incubated in SuperSignal™ 
West Pico PLUS Chemiluminescent Substrate (#34577, Thermo Scientific) mix (2.5 min, gentle 
manual shaking). Finally, Myo16 was visualized using chemiluminescence detection in 
ChemiDoc™Touch. The images were analyzed with ImageJ software (version 2.1.0/1.53c) and Excel 
(version 16.30). 
In addition to Proteintech anti-MYO16, MyBioSource anti-MYO16 (#MBS9609973) was also tested 
for western blotting. The selection of a suitable antibody for western blotting was performed by 
incubating the same membrane first with one antibody, then stripping the membrane, and then 
incubating with the other antibody, similarly to the previous one. The membranes were stripped by 
washing them in TBST (10 min, shaking, at RT), incubating in glycine buffer (0.1 M, pH 2.0) 
(shaking, 1 h), and then washing again in TBST (3 x 10 min, shaking, at RT).  
4.2.3 Preparation and western blotting of U2OS cell lysates  
Western blotting was also performed to U2OS cell lysates in order to verify that MYO16 is 
endogenously expressed in U2OS cells and also to confirm overexpression. For this, transfected cells 
were not fixed but instead washed twice with PBS. 150 l of 1x Laemmli to was added to human 
EGFP-MYO16, rat EGFP-Myo16, EGFP-N1 control, and untransfected control wells, and the cells 
were detached with a scratcher. The cells of four consecutive wells were pooled into one, transferred 
to Eppendorf tubes, and boiled (10 min, at 100C). 25 l of each cell lysate was used in western 
blotting. Western blotting was performed similarly than with mouse tissue samples, except for 
incubation with anti-GFP antibody (1:1000 rabbit polyclonal anti-GFP (#A-11122, Invitrogen) in 5% 





5 Ethical issues 
Instead of using primary cells derived from animals, U2OS cell line, initially derived from human, 
were used in subcellular localization experiments. In order to study myosin XVI localization in the 
brain at different points in development, animals were needed since the brains cannot be examined 
by other means. Mice were selected as a model because the mouse brain is considered relatively 
similar to the human brain in respect to the studied regions.  
All experiments were carried out in accordance with the guidelines laid down with the European 
Communities Council directive of 2010/63/EU and were approved by the County Administrative 
Board of Southern Finland.  
Myo16 knock-out mice were under the University of Helsinki license KEK19-035 (MYO16 in 
psychiatric diseases). 
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actin-related protein 2/3 
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